

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06	Engineering Information Encompass files have new names
NEWS	4	Feb 16	TOXLINE no longer being updated
NEWS	5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07	DGENE Reload
NEWS	8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS	9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS	10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS	11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS	12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS	13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	17	Oct 22	Over 1 million reactions added to CASREACT
NEWS	18	Oct 22	DGENE GETSIM has been improved
NEWS	19	Oct 29	AAASD no longer available
NEWS	20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	22	Nov 29	COPPERLIT now available on STN
NEWS	23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	24	Nov 30	Files VETU and VETB to have open access
NEWS	25	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	26	Dec 10	DGENE BLAST Homology Search
NEWS	27	Dec 17	WELDASEARCH now available on STN
NEWS	28	Dec 17	STANDARDS now available on STN
NEWS	29	Dec 17	New fields for DPCI
NEWS	30	Dec 19	CAS Roles modified
NEWS	31	Dec 19	1907-1946 data and page images added to CA and Caplus
NEWS EXPRESS		August 15	CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:15:24 ON 04 JAN 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 14:16:04 ON 04 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 2 JAN 2002 HIGHEST RN 380300-95-8

DICTIONARY FILE UPDATES: 2 JAN 2002 HIGHEST RN 380300-95-8

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e doxorubicin/cn

E1 1 DOXOMEAN N 98/CN

E2 1 DOXOPHYLLINE/CN

E3 1 --> DOXORUBICIN/CN

E4 1 DOXORUBICIN 14-VALERATE/CN

E5 1 DOXORUBICIN ACETIC ACID SALT/CN

E6 1 DOXORUBICIN AGLYCONE/CN

E7 1 DOXORUBICIN ASCORBIC ACID SALT/CN

E8 1 DOXORUBICIN BENZOIC ACID SALT/CN

E9 1 DOXORUBICIN BIOSYNTHESIS ENZYME DNRV (STREPTOMYCES PEUCETIUS
STRAIN ATCC-29050 GENE DNRV)/CN

E10 1 DOXORUBICIN BIOSYNTHESIS PROTEIN (STREPTOMYCES PEUCETIUS STR
AIN ATCC 29050 GENE DNMT)/CN

E11 1 DOXORUBICIN CITRIC ACID SALT/CN

E12 1 DOXORUBICIN DODECYL SULFATE/CN

=> s e3

L1 1 DOXORUBICIN/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 23214-92-8 REGISTRY

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-

hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-

hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-

OTHER NAMES:

CN 14-Hydroxydaunomycin

CN Caelyx

CN Doxil

CN Doxorubicin

CN FI 106

CN NSC 123127

FS STEREOSEARCH

DR 24385-08-8, 25311-50-6, 23257-17-2, 29042-30-6

MP C27 H29 N O11

CI COW

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSChem, CSNB, DDFU, DIOGENES, DRUGNL,

DRUGPAT,

DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,

MEDLINE,

MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PROMT,

RTECS*,


TOXCENTER, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11155 REFERENCES IN FILE CA (1967 TO DATE)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS (Continued)

752 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

11182 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> e topotecan/cn

E1	1	TOPOSTIN D 654/CN
E2	1	TOPOT/CN
E3	1 -->	TOPOTECAN/CN
E4	1	TOPOTECAN HYDROCHLORIDE/CN
E5	1	TOPOTECAN LACTONE/CN
E6	1	TOPOTECANCARBOXYLIC ACID/CN
E7	1	TOPOTECIN/CN
E8	1	TOPPAN KF-PACK C 500/CN
E9	1	TOPPER 5E/CN
E10	1	TOPREX/CN
E11	1	TOPRILIDINE/CN
E12	1	TOPRIP AZ 1/CN


=> s e3

L2 1 TOPOTECAN/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
 RN 123948-87-8 REGISTRY
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX
 NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (S)-
 OTHER NAMES:
 CN Hycamtamine
 CN Hycamptin
 CN SKF 104864
 CN SKF-S 104864
 CN Topotecan
 CN Topotecan lactone
 FS STEREOSEARCH
 DR 133242-28-1, 138121-88-7
 MF C23 H23 N3 O5
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPIUS, CASREACT, CENB, CEN,
 CHEMCATS,
 CHEMINFORMRX, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
 EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, TOXLIT,
 USAN, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

577 REFERENCES IN FILE CA (1967 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 581 REFERENCES IN FILE CAPIUS (1967 TO DATE)

=> fil .search
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.48	11.63

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 14:16:47 ON 04 JAN 2002

FILE 'CAPLUS' ENTERED AT 14:16:47 ON 04 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:16:47 ON 04 JAN 2002
COPYRIGHT (C) 2002 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 14:16:47 ON 04 JAN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:16:47 ON 04 JAN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s l1 and l2
L3 828 L1 AND L2

=> s l3 and conjugat?
L4 25 L3 AND CONJUGAT?

=> s l4 and hapten?
L5 1 L4 AND HAPTEN?

=> d ibib ab

LS ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER: 2001:199903 USPATFULL
TITLE: Toxicity typing using embryoid bodies
INVENTOR(S): Snodgrass, R. Ralph, San Mateo, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001039006	A1	20011108
APPLICATION INFO.:	US 2001-864621	A1	20010523 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-457931, filed on 8 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-111640	19981209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1759	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods and systems for identifying and typing toxicity of chemical compositions, as well as for screening new compositions for toxicity. The invention involves detecting alterations in gene or protein expression and hence establishing molecular profiles in isolated mammalian embryoid bodies contacted with various chemical compositions of known and unknown toxicities, and correlating the molecular profiles with toxicities of the chemical compositions.

=> s l4 not l5

L6 24 L4 NOT L5

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 22 DUP REM L6 (2 DUPLICATES REMOVED)

=> d ibib ab 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:885838 CAPLUS
 TITLE: Ethylenedicycysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
 INVENTOR(S): Yang, David J.; Liu, Chun-wei; Yu, Dong-fang; Kim, E. Edmund
 PATENT ASSIGNEE(S): Board of Regents The University of Texas System, USA
 SOURCE: PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091807	A2	20011206	WO 2001-US18060	20010601
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
 US 2000-587583 A1 20000602
 US 2000-599152 A1 20000621
 AB The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicycysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.

L7 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:833055 CAPLUS
 TITLE: 135-376739 Cholesterol-free phospholipid liposome compositions for improved drug retention
 INVENTOR(S): Mayer, Lawrence D.; Dos Santos, Nancy; Bally, Marcel B.; Webb, Murray; Tardi, Paul
 PATENT ASSIGNEE(S): Celator Technologies Inc., Can.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085131	A2	20011115	WO 2001-CA655	20010511
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
 US 2000-203399 P 20000511
 AB Substantially cholesterol-free liposomes are provided which demonstrate improved drug retention in vivo. These liposomes comprise: (a) at least 60 mol% a phospholipid comprising 2 satd. fatty acids, the acyl chain of each being the same or different, at least 1 of the acyl chains having more than 18 carbon atoms; (b) 2-15 mol% hydrophilic polymer-conjugated lipids; and (c) up to 38 mol% or more vesicle-forming lipids. Specific embodiments of this invention are vesicles encapsulating idarubicin or topotecan and demonstrating improved drug retention. Also provided is a method for detg. whether retention of a particular drug may be improved by this invention. Thus, pH gradient liposomes consisting of DSPC-PEG2000 (95:5 mol%) DAPC (95:5 mol%) and DBPC (95:5 mol%) were prep'd. and loaded with idarubicin. Except during loading, concns. of lipid and idarubicin were 16.5 and 2.2 mM, resp. Immediately following loading, (within 1-2 h) the liposomes were administered to Balb/C mice and blood samples were removed at 15 and 30 min, 1, 2, 4, 10 and 24 h after i.v. injection and assayed for lipid and idarubicin concns. Cholesterol-free liposomes exhibited enhanced retention of idarubicin as the length of the acyl chain was increased from 18 to 24 carbon atoms.

L7 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2001:338762 CAPLUS
 DOCUMENT NUMBER: 134:362292
 TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
 INVENTOR(S): Farr, Spencer
 PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
 SOURCE: PCT Int. Appl., 222 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
 US 1999-165398 P 19991105
 US 2000-196571 P 20000411
 AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predctd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L7 ANSWER 4 OF 22 USPATFULL
 ACCESSION NUMBER: 2001:224132 USPATFULL
 TITLE: Antioxidant enhancement of therapy for hyperproliferative conditions
 INVENTOR(S): Chinery, Rebecca, Nashville, TN, United States
 Beauchamp, R. Daniel, Nashville, TN, United States
 Coffey, Robert J., Woodside, CA, United States
 Medford, Russell M., Atlanta, GA, United States
 Wadzinski, Brian E., Nashville, TN, United States

PATENT INFORMATION:	NUMBER	KIND	DATE
APPLICATION INFO.:	US 2001049349	A1	20011206
RELATED APPLN. INFO.:	US 2001-779086	A1	20010207 (9)
	Continuation of Ser. No. US 1998-108609, filed on 1 Jul 1998, ABANDONED Continuation of Ser. No. US 1997-967492, filed on 11 Nov 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-886653, filed on 1 Jul 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Sherry M. Knowles, Esq., KING & SPALDING, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	2353		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.

L7 ANSWER 5 OF 22 USPATFULL

ACCESSION NUMBER: 2001:205431 USPATFULL
 TITLE: POLY(DIPEPTIDE) AS A DRUG CARRIER
 INVENTOR(S): XU, JINGYA, WUHAN, China

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041189	A1	20011115
APPLICATION INFO.:	US 1999-291234	A1	19990413 (9)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095

NUMBER OF CLAIMS: 36
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 30 Drawing Page(s)
 LINE COUNT: 1328

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide drug carrier is provided wherein polypeptides containing glutamic acid and aspartic acid, or glutamic acid/alanine,

or glutamic acid/asparagine, or glutamic acid/glutamine, or glutamic acid/glycine, are conjugated to drugs in order to improve the solubility of the drugs and/or their therapeutic efficacy in vivo. An illustrative example involves the conjugation of paclitaxel to a poly(glutamic acid/aspartic acid) polypeptide and its efficacy in the treatment of prostate cancer in vivo.

L7 ANSWER 6 OF 22 USPATFULL

ACCESSION NUMBER: 2001:152518 USPATFULL
 TITLE: Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent
 INVENTOR(S): Singh, Saira Sayed, Los Gatos, CA, United States
 PATENT ASSIGNEE(S): OncoPharmaceutical, Inc., Morgan Hill, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287602	B1	20010911
APPLICATION INFO.:	US 1999-397390		19990915 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100479	19980916 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jarvis, William R. A.	
ASSISTANT EXAMINER:	Kim, Vickie	
LEGAL REPRESENTATIVE:	Wilson, Mark A. Reed & Associates	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	920	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of

a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described.

L7 ANSWER 7 OF 22 USPATFULL

ACCESSION NUMBER: 2001:93131 USPATFULL
 TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
 INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
 Chen, Feng-Jing, Salt Lake City, UT, United States
 PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248363	B1	20010619
APPLICATION INFO.:	US 1999-447690		19991123 (9)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Spear, James M.
 LEGAL REPRESENTATIVE: Reed, Dianne E. Reed & Associates
 NUMBER OF CLAIMS: 57
 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
 LINE COUNT: 3302

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients

contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used

for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

L7 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1

ACCESSION NUMBER: 2000:283948 CAPLUS
 DOCUMENT NUMBER: 132:313704
 TITLE: Therapeutic liposome composition and method of preparation
 INVENTOR(S): Allen, Theresa M.; Uster, Paul; Martin, Francis J.; Zalipsky, Samuel
 PATENT ASSIGNEE(S): Sequus Pharmaceuticals, Inc., USA
 SOURCE: U.S., 17 pp., Cont.-in-part of U.S. 5,891,469.
 CODEN: USXXAM
 LANGUAGE: Patent
 English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6056973	A	20000502	US 1998-138480	19980821
US 5891468	A	19990406	US 1997-949046	19971010
US 6316024	B1	20011113	US 2000-517224	20000302
US 2001038851	A1	20011108	US 2001-876707	20010607
PRIORITY APPLN. INFO.:			US 1996-28269	P 19961011
			US 1997-949046	A2 19971010
			US 1998-138480	A3 19980821
			US 2000-517224	A3 20000302

AB Reagents for use in prepg. a therapeutic liposome compn. sensitized to a target cell are described. The reagents include a liposomal compn. composed of pre-formed liposomes having an entrapped therapeutic agent

and a plurality of targeting conjugates composed of a lipid, a hydrophilic polymer and a targeting ligand. The therapeutic, target-cell sensitized liposome compn. is formed by incubating the liposomal compn. with a selected conjugate. Liposomes were prepd. by mixing partially hydrogenated soybean phosphatidylcholin, cholesterol, and mPEG-DSPE at a molar ratio of 55:40:3 in chloroform and/or methanol in a round bottom flask. The solvents were removed and the dried lipid film produced was hydrated with a buffer to produce large multilamellar vesicles. An anti-E-selectin Fab fragment was conjugated to PEG-DSPE to form a targeting conjugate. An adequate amt. of the Fab-PEG-DSPE conjugate was added to a suspension of the above liposomes and incubated overnight at room temp. for the insertion of the conjugate into preformed liposomes.

REFERENCE COUNT: 7

REFERENCE(S):
 (1) Allen; US 5620689 1997 CAPLUS
 (2) Kiprotin, D; Journal of Liposome Research 1997, V07(04), P391 CAPLUS
 (3) Park, J; Proc Natl Acad Sci USA 1995, V92, P1327 CAPLUS
 (4) Uster, P; FEBS Letters 1996, V386, P243 CAPLUS
 (5) Zalipsky; US 5395619 1995 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:742281 CAPLUS
 DOCUMENT NUMBER: 133:313656
 TITLE: Poly(dipeptide) as a drug carrier
 INVENTOR(S): Xu, Jingya
 PATENT ASSIGNEE(S): Fannin Bioscience, Inc., USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061788	A2	20001019	WO 2000-US9953	20000413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, PT, SE				
US 2001041189	A1	20011115	US 1999-291234	19990413
CN 1310025	A	20010829	CN 2000-105625	20000412
US 1999-291234 A 19990413				
AB A novel polypeptide drug carrier is provided wherein polypeptides contg. glutamic acid and aspartic acid, or glutamic acid/alanine, or glutamic acid/asparagine, or glutamic acid/glutamine, or glutamic acid/glycine, are conjugated to drugs in order to improve the soly. of the drugs and/or their therapeutic efficacy in vivo. An illustrative example involves the conjugation of paclitaxel to a poly(glutamic acid/aspartic acid) polypeptide and its efficacy in the treatment of prostate cancer in vivo.				

L7 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:401690 CAPLUS
 DOCUMENT NUMBER: 133:48878
 TITLE: Oligopeptide prodrug compounds and process for preparation thereof
 INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
 PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.: US 1998-111793 P 19981211 US 1999-119312 P 19990208 WO 1999-US30393 W 19991210				
AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme, trypsin. Also disclosed are processes for making the prodrug compds.				

L7 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:191189 CAPLUS
 DOCUMENT NUMBER: 132:227475
 TITLE: Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent
 INVENTOR(S): Singh, Saira Sayed
 PATENT ASSIGNEE(S): Oncopharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015766	A1	20000323	WO 1999-US21312	19990915
W: AU, CA, JP, KR				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9959253	A1	20000403	AU 1999-59253	19990915
EP 1114144	A1	20010711	EP 1999-946955	19990915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6287602	B1	20010911	US 1999-397390	19990915
PRIORITY APPLN. INFO.: US 1998-100479 P 19980916 WO 1999-US21312 W 19990915				
AB Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amt. of a Golgi app. disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi app. disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described. Nude mice bearing human epithelial (KB-1) tumors were treated with a BFA/chitin/dimethylacetamide compn.				
REFERENCE COUNT: 4				
REFERENCE(S): (1) Barry; US 5439446 A 1995 (2) Canal; US 5536508 A 1996 CAPLUS (3) Dawson; US 4464389 A 1984 CAPLUS (4) Malepeis; US 5696154 A 1997 CAPLUS				

L7 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:686114 CAPLUS
 DOCUMENT NUMBER: 133:271670
 TITLE: Compositions and procedures for preventing aggregation of liposomes
 INVENTOR(S): Cheng, Jui-Ching
 PATENT ASSIGNEE(S): Taiwan Liposome Co., Ltd., Taiwan
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19913640	A1	20000928	DE 1999-19913640	19990325
AB The invention concerns polymeric compns. and procedures for preventing aggregation of pharmaceutical liposomes, including liposomes with their enclosed active components, is characterized by the fact that aggregation is prevented by long-chain polymer-lipid conjugates, whereby liposomal integrity and stability in storage can be increased.				

L7 ANSWER 13 OF 22 USPATFULL
 ACCESSION NUMBER: 2000:109372 USPATFULL
 TITLE: In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-apatial profiles, including tumor sites
 INVENTOR(S): Ranne, David F., Dallas, TX, United States
 PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., Dallas, TX, United States
 States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6106866		20000822
APPLICATION INFO.:	US 1995-509338		19950731 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 72 Drawing Page(s)		
LINE COUNT:	3913		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an anti tumor drug and may be taxol, a peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9% (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protection of the entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the drug migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total dose is required to obtain the desired effect relative to that required for standard agents. Analogous tissue uptake is described for transepithelial migration into the lungs, bladder and bowel.

L7 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:791988 CAPLUS
 DOCUMENT NUMBER: 132:35333
 TITLE: Multibinding inhibitors of topoisomerase
 INVENTOR(S): Linsell, Martin S.; Meier-Davis, Susan; Griffin, John H.
 PATENT ASSIGNEE(S): Advanced Medicine, Inc., USA
 SOURCE: PCT Int. Appl., 142 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 23
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 9964054	A1	19991216	WO 1999-US12908	19990608
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6288234	B1	20010911	US 1999-325662	19990604
AU 9946771	A1	19991210	AU 1999-46771	19990608
EP 1085891	A1	20010328	EP 1999-930179	19990608
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRIORITY APPLN. INFO.:				
		US 1998-88448	P	19980608
		US 1998-93072	P	19980716
		WO 1999-US12908	W	19990608

AB Novel topoisomerase inhibitors that act as multibinding agents, LpXq [where L = a ligand capable of binding to topoisomerase; X = a linker; p =

2-10; q = 1-20; the distance between ligands 2-50. ANG.], are disclosed. Combinatorial arrays, methods of synthesis, and methods of assaying the dimeric and multimeric compds. are also embodied by the invention. A no. of divalent prophetic examples, derived from substituted fused ring heterocyclic ligands and difunctional linkers, are given. Compds. of

this invention are useful in the treatment and prevention of cancer and microbial infections (no data). The multibinding compds. provide greater biol. and/or therapeutic effects than the aggregate of the unlinked ligands due to their multibinding properties (no data). Ligands may include A-62176, A-74932, acridine carboxamides, actinomycin D, AD-312, AD-347, ADMA, AMP-53, amrubicin, amscrine, anthracyclines, asulacrine, azonafide, azatoxin, BBR-2778, BMV-43748, BO-2367, bromodeoxyuridine, C-1310, C-1311, CC-131, CJ-12373, CI-937, CI-920 (fosfotriecin), CP-115953, camptothecin, daunorubicin, doxorubicin, DuP 937 (losoxanthrone), DuP 941, elinafide, ellipticine-nitradol (conjugates), elasmotrucin, ER-17328, etoposide, fleroxacin, GI-149893, GL-331, GR-122222X, ICRF-154,

ICRF-193, idarubicin, iododoxorubicin, IST-622, KRO-10018, intoplicine, lomefloxacin, losoxanthrone, m-AMSA, merbarone, meraboin, mitonafide, mitoxanthrone, morindone, NCA-0465, NK-109, NK-611, NSC-655649, NSC-65517,

NSC-675967, pazelliptine, pazufloxacin, PD-131112, piroxanthrone, pyridobenzophenoxazine, S-16020-2, saintopin, sitafloxacin hydrate,

L7 ANSWER 14 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2000318496 EMBASE
 TITLE: The therapeutic potential of flavonoids.
 AUTHOR: Wang H.-K.
 CORPORATE SOURCE: H.-K. Wang, University of North Carolina, Beard Hill, Chapel Hill, NC 27599-7360, United States.
 SOURCE: hwang@email.unc.edu
 Expert Opinion on Investigational Drugs, (2000) 9/9 (2103-2119).
 Refs: 92
 ISSN: 1354-3784 CODEN: EOIDER
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 016 Cancer
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB Four most widely investigated flavonoids, flavopiridol, catechins, genistein and quercetin are reviewed in this article. Flavopiridol is a novel semisynthetic flavone analogue of rohitukine, a leading anticancer compound from an Indian tree. Flavopiridol inhibits most cyclin-dependent kinases and displays unique anticancer properties. It is the first cyclin-dependent kinase inhibitor to be tested in Phase II clinical trials. Catechin and its gallate are major ingredients in green tea and their anti-oxidant and cancer preventive effects have been widely investigated. A Phase I study of green tea extract GTE-TP91 has been conducted in adult patients with solid tumours. Similarly, genistein is a major ingredient in soybean and has been shown to prevent cancer and have antitumour, anti-oxidant and anti-inflammatory effects. Two antibody-genistein conjugates, B43-genistein and EGF-genistein, are currently in clinical development for the treatment of acute lymphoblastic leukaemia and breast cancer, respectively. Finally, most recent updates of quercetin are briefly described.

L7 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2002 ACS (Continued)
 SH-22995, sobuzoxane, SR-103, TAS-103, teloxanthrone, teniposide, TLC-D-99,
 top-53, topotecan, tosuflaxacin, TRK-710, trovafloxacin, UCE-6, VM-26, VP-16, WSR, WIN-33377, WIN-58161, WIN-645593, WQ-2743, WQ-3034, WR-63320, XR-5942, XR-5000, and 773U82.
 REFERENCE COUNT: 5
 REFERENCE(S):
 (1) Brown; Antibiotic and Chemotherapy 7th Ed 1997, P419 CAPLUS
 (2) Ehrhardt; Antimicrobial Agents and Chemotherapy 1997, V41(11), P2570 CAPLUS
 (3) Fan; J Med Chem 1995, V38(3), P408 CAPLUS
 (4) NEORX Corporation; WQ 9205802 A1 1992 CAPLUS
 (5) Shuker; Science 1996, V274, P1531 CAPLUS

L7 ANSWER 16 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 1999173261 EMBASE
 TITLE: A novel hypothesis for the mechanism of action of p-glycoprotein as a multidrug transporter.
 AUTHOR: Bao Ting Zhu
 CORPORATE SOURCE: B.T. Zhu, Dept. of Basic Pharmacol. Sciences, College of Pharmacy, University of South Carolina, 700 Sumter Street, Columbia, SC 29208, United States
 SOURCE: Molecular Carcinogenesis, (1999) 25/1 (1-13).
 Refs: 69
 ISSN: 0899-1987 CODEN: MOCAES
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB For years, P-glycoprotein (P-gp) has been purported to be a membrane transporter capable of selectively transporting many (but not all) lipophilic anticancer drugs with diverse chemical structures. Because the alleged functions of P-gp provide a straightforward, near-perfect explanation for the molecular mechanism of multidrug resistance associated with P-gp overexpression. However, the exact molecular mechanism for P-gp's purported function has never been clearly understood since its initial discovery some 20 yr ago. In this paper, I develop a novel working hypothesis regarding the mechanism of P-gp's action and suggest that P-gp is an energy-dependent efflux pump only for certain conjugated metabolites (probably sulfates) of the lipophilic anticancer drugs but not for the parent compounds, as was always claimed. According to this hypothesis, P-gp overexpression in most cases is not the 'culprit' but instead an 'accomplice' in P-gp-associated multidrug resistance. The culprit is probably the enhanced function of the metabolizing enzymes for the lipophilic anticancer drugs. This hypothesis also predicts that one of the important physiological functions of P-gp is to be part of an intracellular machinery (together with the phase I and II metabolizing enzymes) for the metabolism, detoxification, and disposition of lipophilic endogenous chemicals as well as xenobiotics, including cytotoxic anticancer drugs. There exists a considerable body of circumstantial evidence in the literature that lends strong support to this mechanistic hypothesis of P-gp's action as well as to the predicted physiological functions of P-gp. It will be of considerable interest to examine this novel hypothesis experimentally.

L7 ANSWER 18 OF 22 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 1998054633 EMBASE
 TITLE: Total synthesis of stitipamide and designed polyenes as new agents for the reversal of multidrug resistance.
 AUTHOR: Andrus M.B.; Lepore S.D.; Turner T.M.
 CORPORATE SOURCE: M.B. Andrus, Department of Chemistry/Biochemistry, Brigham Young University, Provo, UT 84602, United States.
 SOURCE: Journal of the American Chemical Society, (17 Dec 1997) 119/50 (12159-12169).
 ISSN: 0002-7863 CODEN: JACSAT
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 029 Clinical Biochemistry
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 AB The synthesis of (-)-stitipamide (1) is reported together with the designed enynes 2 (6,7-dehydrostitipamide) and 3 that are now shown to reverse the multidrug resistance (MDR) of human breast cancer cells (MCF-7adrR). Stitipamide was assembled using a Stille coupling with (E)-vinyl iodide 17 and (Z)-stannyl amide 16 in 78% yield. (E)-Vinyl iodide 17 was made using a Takai reaction and a selective dihydroxylation of the terminal olefin of nonconjugated diene 7 using the Sharpless AD-mix reagent. The precursor 16, (E,Z)-stannyl diene ester 13, was assembled with high selectivity in a single operation using a tandem syn-addition of tributyltin cuprate to acetylene followed by conjugate addition to ethyl propiolate. Structural variants 2 and 3 were assembled using palladium-catalyzed Sonogashira couplings with vinyl iodides 17 and 35 and acetylenes 22 and 26 in high yield at near 1:1 stoichiometry. Compound 2 was found to be far less toxic than stitipamide and performed much better as an MDR reversal agent. Compound 3 was better still due to even lower toxicity.

L7 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
 ACCESSION NUMBER: 1998:508915 CAPLUS
 DOCUMENT NUMBER: 129:156924
 TITLE: Camptothecin drug combinations and methods with reduced side effects
 INVENTOR(S): Ratain, Mark J.; Gupta, Elora
 PATENT ASSIGNEE(S): Arch Development Corporation, USA
 SOURCE: U.S., 44 pp. Cont.-in-part of U.S. Ser. No. 271,278, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5786344	A	19980728	US 1995-423641	19950417
WO 9601127	A1	19960118	WO 1995-US8394	19950705
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2194277	AA	19960118	CA 1995-2194277	19950705
AU 9529595	A1	19960125	AU 1995-29595	19950705
EP 768895	A1	19970423	EP 1995-925476	19950705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10505579	T2	19980602	JP 1995-503964	19950705
PRIORITY APPLN. INFO.: US 1994-271278 19940705				
US 1995-423641 19950417				
WO 1995-US8394 19950705				
AB Methods, combination formulations, and kits are provided to reduce the toxicity of camptothecin drugs, e.g. irinotecan (CPT-11). Therapeutic and treatment methods are disclosed which employ such drugs in combination with agents that increase conjugative enzyme activity or glucuronoyl transferase activity, and agents that decrease biliary transport protein activity, e.g. cyclosporine A, the resultant effects of which are to decrease the significant side effects previously assocd. with treatment using these drugs.				

L7 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:529503 CAPLUS
 DOCUMENT NUMBER: 125:177401
 TITLE: Complexes of dermatan sulfate and drugs with improved pharmacokinetics
 INVENTOR(S): Renney, David F.
 PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 227 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619242	A1	19960627	WO 1994-US14776	19941222
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2208566	AA	19960627	CA 1994-2208566	19941222
AU 9515537	A1	19960710	AU 1995-15537	19941222
AU 709008	B2	19990819		
EP 794796	A1	19970917	EP 1995-907242	19941222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10510831	T2	19981020	JP 1994-519745	19941222
PRIORITY APPLN. INFO.: WO 1994-US14776 19941222				
AB A drug carrier compn. comprising a drug complexed with dermatan sulfate (I), with a sulfur content of up to 9 %, is disclosed. The compns. are administered in a fashion that allows efficient vascular access and induced the following in vivo effects (1) rapid partial or total endothelial envelopment of the drug (diagnostic) carrier; (2) sequestration of the carrier and protection of the entrapped agent or blood vascular clearance at an early time (2 min) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; (3) acceleration of the carrier's transport across and/or through the vascular endothelium or subendothelial structures into the tissue compartment (intestitium); and (4) improvement of the efficiency with which the drug migrates across the endothelium of epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for std. agents. Analogous tissue uptake is described for transmembrane migration into the lungs, bladder and bowel. A soln. of 10 mg I/mL was stirred with a soln. of 4 mg doxorubicin (II)/mL and homogenized to obtain I:II complex. The soln. was filtered, followed by addn. of 3 mL of 500 mg/mL saccharose and 1.5 mL of 10 mg/mL PEG, the resulting soln. was then filtered and lyophilized. The MIC50 of the complex against II-resistant human breast carcinoma cell was 0.81-0.89 as compared to 22.28 .mu.M for II alone.				

L7 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:377089 CAPLUS
 DOCUMENT NUMBER: 125:49345
 TITLE: Compounds, pharmaceutical composition and diagnostic system comprising same, and their use
 INVENTOR(S): Trouet, Andre; Baurain, Roger
 PATENT ASSIGNEE(S): La Region Wallonne, Belg.; Baurain, Roger
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605863	A1	19960229	WO 1995-BE76	19950821
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RM: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BE 1008581	A3	19960604	BE 1994-752	19940819
BE 1008580	A3	19960604	BE 1994-751	19940819
CA 2203622	AA	19960229	CA 1995-2203622	19950821
AU 9532486	A1	19960314	AU 1995-32486	19950821
AU 694546	B2	19980723		
EP 769967	A1	19970502	EP 1995-928905	19950821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508291	T2	19980818	JP 1995-507662	19950821
NO 9700748	A	19970410	NO 1997-748	19970218
US 5962216	A	19991005	US 1997-793910	19970401
PRIORITY APPLN. INFO.:			BE 1994-751	19940819
			BE 1994-752	19940819
			WO 1995-BE76	19950821

OTHER SOURCE(S): MARPAT 125:49345
 AB The compds. W-Z-M of the invention comprise an element M, selected from markers and therapeutic agents having an intracellularly active site, linked to a ligand W-Z having an arm Z linked to a terminal group W. The bond between the arm Z of the ligand W-Z and the element M prevents the compd. (W-Z-M) from penetrating within the cells and/or inhibits expression of the marker M. This bond is selectively cleaved by factors secreted by target cells so as to enable the marker M to be expressed in the target cells or the therapeutic agent W to penetrate therein; the terminal group W ensures that the compd. (W-Z-M) is stable in serum and circulating blood. Data are presented for e.g. effect of .beta.-Ala-L-Leu-L-Ala-L-Leu-daunorubicin conjugate with mammary carcinoma cells. Also described is characterization of protease(s) secreted into the extracellular medium and able to hydrolyze .beta.-Ala-Leu-Ala-Leu-doxorubicin.

L7 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:209682 CAPLUS
 DOCUMENT NUMBER: 124:250911
 TITLE: Camptothecin drug combinations and medicaments with reduced side effects
 INVENTOR(S): Ratain, Mark J.; Gupta, Elora
 PATENT ASSIGNEE(S): Arch Development Corporation, USA
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9601127	A1	19960118	WO 1995-US8394	19950705
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RM: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5786344	A	19980728	US 1995-423641	19950417
AU 9529595	A1	19960125	AU 1995-29595	19950705
EP 768895	A1	19970423	EP 1995-925476	19950705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10505579	T2	19980602	JP 1995-503964	19950705
PRIORITY APPLN. INFO.:			US 1994-271278	19940705
			US 1995-423641	19950417
			WO 1995-US8394	19950705
AB Methods, combination formulations, and kits are provided to reduce the toxicity of camptothecin drugs, e.g. irinotecan (CPT-11). Disclosed are therapeutics and treatment methods employing such drugs in combination with agents that increase conjugative enzyme activity or glucuronosyltransferase activity, and agents that decrease biliary transport protein activity, e.g. cyclosporine A, the resultant effects of which are to decrease the significant side effects previously assocd. with treatment using these drugs.				

L7 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1992:99301 CAPLUS
 DOCUMENT NUMBER: 116:99301
 TITLE: Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasm inhibitors
 INVENTOR(S): Bach, Ardalan; Shanahan, William R., Jr.
 PATENT ASSIGNEE(S): Searle, G. D., and Co., USA
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 193575	A1	19901024	EP 1990-107246	19900417
EP 393575	B1	19940316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2014732	AA	19901017	CA 1990-2014732	19900417
JP 02292227	A2	19901203	JP 1990-101530	19900417
AT 102838	E	19940415	AT 1990-107246	19900417
ES 2062155	T3	19941216	ES 1990-107246	19900417
PRIORITY APPLN. INFO.:			US 1989-339503	19890417
			EP 1990-107246	19900417

OTHER SOURCE(S): MARPAT 116:99301
 AB Half-amide/half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbimide (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasm inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

=> s antibod? or conjugat?

L8 2261492 ANTIBOD? OR CONJUGAT?

=> s l8 and (therapeu?)

L9 130589 L8 AND (THERAPEU?)

=> s l9 and target?

L10 33474 L9 AND TARGET?

=> s l10 and (tumor? or tumour? or diseases?)

3 FILES SEARCHED...

L11 28384 L10 AND (TUMOR? OR TUMOUR? OR DISEAS?)

=> s l112 and (haptent? or drug? or polymer? or peg? or liposome? or dna? or peptid?
or oligonucleotid? or enzyme? or prodrug?)

L112 NOT FOUND

The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l11 and (haptent? or drug? or polymer? or peg? or liposome? or dna? or peptid?
or oligonucleotid? or enzyme? or prodrug?)

4 FILES SEARCHED...

L12 25011 L11 AND (HAPTEN? OR DRUG? OR POLYMER? OR PEG? OR LIPOSOME? OR
DNA? OR PEPTID? OR OLIGONUCLEOTID? OR ENZYME? OR PRODRUG?)

=> s l12 and (target? and therapeutic(w)agent? and (conjugat? or antibod?))

L13 8094 L12 AND (TARGET? AND THERAPEUTIC(W) AGENT? AND (CONJUGAT? OR
ANTIBOD?))

L15 ANSWER 1 OF 15 USPATFULL
 ACCESSION NUMBER: 2001:152454 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6287536	B1	20010911
US 1997-788339		19970127 (8)

APPLICATION INFO.: Division of Ser. No. US 1993-122979, filed on 16 Sep 1993, now patented, Pat. No. US 5630996 Continuation of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Saunders, David
 LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group PLLC
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 4802

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

L15 ANSWER 3 OF 15 USPATFULL
 ACCESSION NUMBER: 2000:17822 USPATFULL
 TITLE: Treatment methods using homeopathic preparations of growth factors
 INVENTOR(S): Brewitt, Barbara A., 5557 36.sup.th Ave. NE., Seattle, WA, United States 98105

NUMBER	KIND	DATE
US 604734		20000215
US 1997-855096		19970513 (8)

APPLICATION INFO.: Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996, now patented, Pat. No. US 5629286, issued on 13 May 1997 which is a continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: McDermott, Corrine
 ASSISTANT EXAMINER: Gring, Kent
 LEGAL REPRESENTATIVE: Speckman, Ann W., Sleath, Janet
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 30 Drawing Figure(s); 34 Drawing Page(s)
 LINE COUNT: 2005

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer, diabetes and depression. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

L15 ANSWER 2 OF 15 USPATFULL
 ACCESSION NUMBER: 2000:67428 USPATFULL
 TITLE: Mesothelial cell gene therapy
 INVENTOR(S): Shockley, Ty Robert, Highland Park, IL, United States
 Jackman, Robert William, Brookline, MA, United States
 Nagy, Janice Ann, Brookline, MA, United States
 PATENT ASSIGNEE(S): Beth Israel Hospital Association, Boston, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6068837		20000530
US 1997-984103		19971203 (8)

APPLICATION INFO.: Continuation of Ser. No. US 1996-625771, filed on 29 Mar 1996 which is a division of Ser. No. US 1993-80474, filed on 18 Jun 1993, now patented, Pat. No. US 5645829

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: LeGuyader, John L.
 ASSISTANT EXAMINER: Kaushal, Sumesh
 LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1,4
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 1830

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods and pharmaceutical compositions for modifying the mesothelial cells of a mammalian recipient in situ are provided. The methods include forming a mesothelial cell expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial cells). The mesothelial cell expression system is useful for the localized and systemic delivery of therapeutic agents in situ.

L15 ANSWER 4 OF 15 USPATFULL
 ACCESSION NUMBER: 1999:113890 USPATFULL
 TITLE: Biotinidase resistant biotin-DOTA conjugates
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5955605		19990921
US 1996-695940		19960812 (8)

APPLICATION INFO.: Division of Ser. No. US 1995-351469, filed on 21 Feb 1995, now patented, Pat. No. US 5608060

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eizenschenk, Frank C.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 24 Drawing Page(s)
 LINE COUNT: 4727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

L15 ANSWER 5 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:115714 USPATFULL
 TITLE: Pharmaceutical dipeptide compositions and methods of use thereof; immunodepressants
 INVENTOR(S): Khavinson, Vladimir Kh., St. Petersburg, Russian Federation
 Morozov, Vyacheslav G., St. Petersburg, Russian Federation
 PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5811399		19980922
US 4509048		19950526 (8)
Continuation-in-part of Ser. No. 278463, filed on Jul 1994, now abandoned And Ser. No. 337341, filed on 10 Nov 1994, now patented, Pat. No. 5538951		
which is a continuation-in-part of Ser. No. 257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. 783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. 678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. 415283, filed on Aug 1989, now abandoned		
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Harle, Jennifer	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	8863	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R'-Glu-Trp-R' pharmaceutical preparation useful in subjects having autoimmune diseases.	

L15 ANSWER 7 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:104409 USPATFULL
 TITLE: Method for loading lipid vesicles
 INVENTOR(S): Hope, Michael, Vancouver, Canada
 Cullis, Pieter R., Vancouver, Canada
 Fenske, David, Surrey, Canada
 Wong, Kim, Vancouver, Canada
 PATENT ASSIGNEE(S): University of British Columbia, Vancouver, Canada (non-U.S. corporation)

NUMBER	KIND	DATE
US 5800833		19980901
US 1995-399692		19950227 (8)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1016	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Methods for the preparation of stable liposome formulations of protonatable therapeutic agents. The methods involve loading a therapeutic agent into preformed liposomes having a methylamine concentration gradient across the lipid bilayer of the liposomes. These methods provide liposome formulations which are more stable, more cost effective, and easier to prepare in a clinical environment than those previously available. The present invention also provides the pharmaceutical compositions prepared by the above methods, a kit for the preparation of liposome formulations of therapeutic agents, and methods for their use.	

L15 ANSWER 6 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:111911 USPATFULL
 TITLE: Method for treatment of purulent inflammatory diseases
 INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian Federation
 Khavinson, Vladimir Kh., St. Petersburg, Russian Federation
 PATENT ASSIGNEE(S): Cytoven J.V., Kirkland, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5807830		19980915
US 1995-452061		19950526 (8)
Continuation-in-part of Ser. No. US 1994-337341, filed on 10 Nov 1994, now patented, Pat. No. US 5538951 And continuation-in-part of Ser. No. US 1994-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned		
PRIORITY INFORMATION:	SU 1987-4352833	19871230
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jones, W. Gary	
ASSISTANT EXAMINER:	Fredman, Jeffrey	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	8879	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention provides methods of treating purulent inflammatory diseases by administering L-Glu-L-Trp or a salt thereof.	

L15 ANSWER 8 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:88491 USPATFULL
 TITLE: Method for loading lipid vesicles
 INVENTOR(S): Hope, Michael, Vancouver, Canada
 Cullis, Pieter R., Vancouver, Canada
 Fenske, David B., Surrey, Canada
 Wong, Kim F., Vancouver, Canada
 PATENT ASSIGNEE(S): The University of British Columbia, Canada (non-U.S. corporation)

NUMBER	KIND	DATE
US 5785987		19980728
US 1996-607614		19960227 (8)
Continuation-in-part of Ser. No. US 1995-399692, filed on 27 Feb 1995		
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	1304	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Methods for the preparation of stable liposome formulations of protonatable therapeutic agents. The methods involve loading a therapeutic agent into preformed liposomes having a methylamine concentration gradient across the lipid bilayer of the liposomes. These methods provide liposome formulations which are more stable, more cost effective, and easier to prepare in a clinical environment than those previously available. The present invention also provides the pharmaceutical compositions prepared by the above methods, a kit for the preparation of liposome formulations of therapeutic agents, and methods for their use.	

L15 ANSWER 9 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:72601 USPATFULL
 TITLE: Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
 INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian Federation
 Khavinson, Vladimir Kh., St. Petersburg, Russian Federation
 PATENT ASSIGNEE(S): Cytran, Inc., Kirkland, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5770576		19980623
US 1995-452077		19950526 (8)

RELATIONSHIP INFO.: Continuation of Ser. No. US 1994-337341, filed on 10 Nov 1994, now patented, Pat. No. US 5538951 which is a division of Ser. No. US 1989-415283, filed on 30 Aug 1989 And a continuation-in-part of Ser. No. US 1994-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a

continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Robinson, Douglas W.
 ASSISTANT EXAMINER: Harle, Jennifer
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 8823

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods of treatment of subjects with systemic toxicity by administering an R'-Glu-Trp-R' pharmaceutical preparation.

L15 ANSWER 10 OF 15 USPATFULL
 ACCESSION NUMBER: 1998:28061 USPATFULL
 TITLE: Methods for normalizing numbers of lymphocytes
 INVENTOR(S): Morozov, Vyacheslav G., St. Petersburg, Russian Federation
 Khavinson, Vladimir Kh., St. Petersburg, Russian Federation
 PATENT ASSIGNEE(S): Cytoven J.V., Kirkland, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5728680		19980317
US 1995-452411		19950526 (8)

RELATIONSHIP INFO.: Continuation-in-part of Ser. No. US 1994-337341, filed on 10 Nov 1994, now patented, Pat. No. US 5538951 And a continuation-in-part of Ser. No. US 1994-278463, filed on 21 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-257495, filed on 7 Jun 1994, now abandoned which is a continuation of Ser. No. US 1991-783518, filed on 28 Oct 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-678129, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-415283, filed on 30 Aug 1989, now abandoned

PRIORITY INFORMATION: SU 1987-4352833 19871230
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Feisee, Lila
 ASSISTANT EXAMINER: Ungar, Susan
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 16 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 8309

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Trp.

L15 ANSWER 11 OF 15 USPATFULL
 ACCESSION NUMBER: 97:5894 USPATFULL
 TITLE: Mesothelial cell gene therapy
 INVENTOR(S): Shockley, Ty Robert, Highland Park, IL, United States
 Jackman, Robert William, Brookline, MA, United States
 Nagy, Janice Ann, Brookline, MA, United States
 PATENT ASSIGNEE(S): Beth Israel Hospital Association, Brookline, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5645829		19970708
US 1993-80474		19930618 (8)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Chambers, Jasmine C.
 LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 15
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 1879

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods and pharmaceutical compositions for modifying the mesothelial cells of a mammalian recipient in situ are provided. The methods include forming a mesothelial cell expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial cells). The mesothelial cell expression system is useful for the localized and systemic delivery of therapeutic agents in situ.

L15 ANSWER 12 OF 15 USPATFULL
 ACCESSION NUMBER: 97:42628 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5630996		19970520
US 1993-122979		19930916 (8)

RELATIONSHIP INFO.: Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 4768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

L15 ANSWER 13 OF 15 USPATFULL
 ACCESSION NUMBER: 97:40765 USPATFULL
 TITLE: Homeopathic dilutions of growth factors
 INVENTOR(S): Brewitt, Barbara, 5557 - 36th Ave. NE., Seattle, WA, United States 98105-2313

NUMBER	KIND	DATE
US 5629286		19970513
US 1996-710040		19960910 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Hafer, Robert A.
 ASSISTANT EXAMINER: Smith, Chalin
 LEGAL REPRESENTATIVE: Speckman, Ann W., Sleath, Janet
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 29 Drawing Figure(s); 24 Drawing Page(s)
 LINE COUNT: 1409

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include chronic viral disorders, such as HIV, AIDS, chronic fatigue syndrome and Epstein-Barr viral infections, cancer and diabetes. Homeopathic dilutions of growth factors are preferably administered orally. In an alternative embodiment, patients are treated with radio frequency signals corresponding to homeopathic dilutions of growth factors.

L15 ANSWER 14 OF 15 USPATFULL
 ACCESSION NUMBER: 97:18284 USPATFULL
 TITLE: Biotinidase-resistant biotin-DOTA conjugates
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5608060		19970304
WO 9325240		19931223
US 1995-351469		19950221 (8)
WO 1993-US5406		19930607
		19950221 PCT 371 date
		19950221 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 4732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

L15 ANSWER 15 OF 15 USPATFULL
 ACCESSION NUMBER: 97:77958 USPATFULL
 TITLE: Chemically defined polymeric carriers for release of covalently linked agents
 INVENTOR(S): Srinivasan, Ananthachari, St. Charles, MO, United States
 Vrudhula, Vivekananda M., Edmonds, WA, United States
 Brixner, Diana I., Lynnwood, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5549883		19960827
US 1993-71357		19930603 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-765126, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-590086, filed on 28 Sep 1990, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Wu, Shean
 ASSISTANT EXAMINER: Chapman, Lara E.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 1332

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A chemically defined polymeric carrier comprising a series of .alpha.-amino acids in any combination containing side chains to which diagnostic/therapeutic and chelating agents can be covalently joined through cleavable linkers either directly or covalently joined through cleavable linkers after chemical modification of the side chains. Hydrasone, disulfide, and ester linkages in any combination can be present in the polymeric carrier between the side chains of the .alpha.-amino acids and the agents. The presence of a particular covalent linkage between the side chain and the agent in the carrier is determined by the functional group present in the side chain of the .alpha.-amino acid and the functional group present in the agent. The .alpha.-amino acids with side chains to which agents do not covalently join can function as spacers to minimize interaction between bulky molecules attached to the polymeric carrier. In addition, those .alpha.-amino acids with charged or hydrophilic side chains to which agents do not covalently join can provide increased solubility to the polymeric carrier.

```
=> s l13 and therapeutic(w)agents
L16      6546 L13 AND THERAPEUTIC(W) AGENTS

=> s l16 and (tumor? or tumour? or infectious(w)disease?)
L17      4803 L16 AND (TUMOR? OR TUMOUR? OR INFECTIOUS(W) DISEASE?)

=> s l17 and composition?
L18      4084 L17 AND COMPOSITION?

=> s l18 and hapten?
L19      449 L18 AND HAPTEN?

=> s l18 and epitopes
L20      1472 L18 AND EPITOPES

=> s l18 and multiple(w)epitopes
L21      50 L18 AND MULTIPLE(W) EPITOPES

=> dup rem l21
PROCESSING COMPLETED FOR L21
L22      50 DUP REM L21 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 50 ANSWERS - CONTINUE? Y/(N):y
```

L22 ANSWER 1 OF 50 USPATFULL

ACCESSION NUMBER: 2001:237475 USPATFULL
 TITLE: TRANSPLANTATION OF NEURAL CELLS FOR THE TREATMENT OF
 CHRONIC PAIN OR SPASTICITY
 INVENTOR(S): DINSMORE, JONATHAN, BROOKLINE, MA, United States
 SIEGAN, JULIE, BOSTON, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055587	A1	20011227
APPLICATION INFO.:	US 1998-163684	A1	19980930 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	1775		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using neural cells to treat chronic pain and/or spasticity are described. The neural cells can be derived from any mammal, and are preferably human or porcine in origin. The neural cells preferably are serotonergic cells or are gamma-aminobutyric acid (GABA)-producing cells. Neural cells can be obtained from adult, juvenile, embryonic or fetal donors. Neural cells can be modified to be suitable for transplantation into a subject. For example, the neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the

cell surface which is capable of stimulating an immune response against the cell in a subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject or can be genetically modified to produce a factor. In one embodiment, the neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The neural cells of the present invention can be used to treat chronic pain and/or spasticity

by delivering the cells into the spinal cord of a subject.

L22 ANSWER 2 OF 50 USPATFULL

ACCESSION NUMBER: 2001:233127 USPATFULL
 TITLE: PORCINE CARDIOMYOCYTES AND THEIR USE IN TREATMENT OF
 INSUFFICIENT CARDIAC FUNCTION
 INVENTOR(S): DINSMORE, JONATHAN, BROOKLINE, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001053154	A1	20011220
APPLICATION INFO.:	US 1999-270145	A1	19990316 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-454989, filed on 30 May 1995, GRANTED, Pat. No. US 5919449		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	1657		

AB Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be modified to be suitable for transplantation into a xenogeneic subject, such as a human.

For example, the porcine cardiomyocytes can be modified such that an antigen (e.g., an MHC class I antigen) on the cardiomyocyte surface which is capable of stimulating an immune response against the cardiomyocytes in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cardiomyocyte when introduced into the subject. In one embodiment, the porcine cardiomyocytes are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine cardiomyocytes of the present invention can be used to treat disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a xenogeneic subject by administering the cardiomyocytes to the subject.

L22 ANSWER 3 OF 50 USPATFULL

ACCESSION NUMBER: 2001:193944 USPATFULL
 TITLE: Method and composition for reconstituting
 multi-epitopic antigens to initiate an immune response
 INVENTOR(S): Madiyalakan, Ragupathy, Edmonton, Canada
 Noujaim, Antoine A., Edmonton, Canada
 Baum, Richard P., Hargeshheim, Germany, Federal
 Republic

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036457	A1	20011101
APPLICATION INFO.:	US 2001-071339	A1	20010531 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-913290, filed on 20 Mar 1998, GRANTED, Pat. No. US 6241985		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1996-18461	19960515
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1234	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.

L22 ANSWER 4 OF 50 USPATFULL

ACCESSION NUMBER: 2001:171199 USPATFULL
 TITLE: Anti-TNF antibodies and peptides of
 human tumor necrosis factor
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Daddona, Peter, Menlo Park, CA, United States
 Ghayeb, John, Downingtown, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott, Westborough, MA, United States
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001027249	A1	20011004
APPLICATION INFO.:	US 2001-756301	A1	20010108 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-133119, filed on 12 Aug 1998, PENDING Division of Ser. No. US 1995-570674, filed on 11 Dec 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-324799, filed on 18 Oct 1994.		

GRANTED, Pat. No. US 5698195 Continuation-in-part of Ser. No. 1994-192102, filed on 4 Feb 1994, GRANTED, Pat. No. US 5656272 Continuation-in-part of Ser. No. US 1994-192861, filed on 4 Feb 1994, GRANTED, Pat. No. US 5919452 Continuation-in-part of Ser. No. US 1994-192093, filed on 4 Feb 1994, PENDING Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, ABANDONED

	NUMBER	DATE
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Carolyn S. Elmore, HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Page(s)	
LINE COUNT:	5577	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor- α (TNF- α) and are useful in vivo diagnosis and therapy of a number of TNF- α -mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

L22 ANSWER 5 OF 50 USPATFULL

ACCESSION NUMBER: 2001:144923 USPATFULL
 TITLE: Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
 INVENTOR(S): Reed, Steven G., Bellevue, WA, United States
 Xu, Jiangchun, Bellevue, WA, United States
 Dillon, Devin C., Redmond, WA, United States

NUMBER	KIND	DATE
US 2001018058	A1	20010830
US 2000-745288	A1	20001219 (9)

RELATED APPL. INFO.: Division of Ser. No. US 1999-288950, filed on 9 Apr 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248178, filed on 9 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-118627, filed on 17 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1997-998253, filed on 24 Dec 1997, ABANDONED

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Jane E. R. Potter, Seed Intellectual Property Law Group
 PLLC, Suite 6300, 701Fifth Avenue, Seattle, WA, 98104-7092

NUMBER OF CLAIMS: 60
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 3164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds and methods for the treatment and diagnosis of breast cancer are provided. The inventive compounds include polypeptides containing at least a portion of a breast tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of breast cancer comprising such polypeptides, or polynucleotides encoding such polypeptides, are also provided, together with polynucleotides for preparing the inventive polypeptides.

L22 ANSWER 7 OF 50 USPATFULL

ACCESSION NUMBER: 2001:163053 USPATFULL
 TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 INVENTOR(S): Isaacson, Ole, Cambridge, MA, United States
 Dinsmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): The McLean Hospital Corporation, Belmont, MA, United States (U.S. corporation)
 Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6294383	B1	20010925
US 1995-424851		19950419 (8)

RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Saoud, Christine J.
 ASSISTANT EXAMINER: Turner, Sharon L.
 LEGAL REPRESENTATIVE: Lahive & Cockfield LLP, Mandragouras, Esq., Amy E., Williams, Esq., Megan E.

NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 49 Drawing Figure(s); 21 Drawing Page(s)
 LINE COUNT: 4123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

L22 ANSWER 6 OF 50 USPATFULL

ACCESSION NUMBER: 2001:185062 USPATFULL
 TITLE: Leptospiral major outer membrane protein Lipl32
 INVENTOR(S): Haske, David A., Culver City, CA, United States
 PATENT ASSIGNEE(S): The University of California, Oakland, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6306623	B1	20011023
US 1998-28586		19980224 (9)

RELATED APPL. INFO.: Division of Ser. No. US 1997-998253, filed on 24 Dec 1997, ABANDONED

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Navarro, Mark
 LEGAL REPRESENTATIVE: Gray Cary Ware Freidenrich, Haile, Lisa A.
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 1502

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB An antigenic preparation is provided containing an outer membrane protein associated with pathogenic strains of Leptospira. The protein has been designated "Lipl32" for "lipoprotein from Leptospira" and because the isolated polypeptide migrates to a position corresponding to a molecular weight of 32 kD in a denaturing polyacrylamide gel. The invention provides polynucleotides encoding Lipl32 and antibodies that bind the protein which are useful in the diagnosis of leptospirosis. In addition, Lipl32 can be used immunologically as a vaccine for spirochete-associated pathologies.

L22 ANSWER 8 OF 50 USPATFULL

ACCESSION NUMBER: 2001:147682 USPATFULL
 TITLE: Anti-TNFA antibodies and assays employing anti-TNFA antibodies
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Dadonna, Peter, Palo Alto, CA, United States
 Ghayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott A., Westborough, MA, United States
 PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6284471	B1	20010904
US 1994-192093		19940204 (8)

RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Caputa, Anthony C.
 ASSISTANT EXAMINER: Canella, Karen A.
 LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 48 Drawing Figure(s); 36 Drawing Page(s)
 LINE COUNT: 5032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.

L22 ANSWER 9 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:136770 USPATFULL
 TITLE: Anti-TNF antibodies and peptides of human tumor necrosis factor
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Daddona, Peter, Menlo Park, CA, United States
 Ghayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott, Westborough, MA, United States
 PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)
 New York University Medical Center, New York, NY, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6277969	B1	20010821
US 1996-133119		19960812 (9)
Division of Ser. No. US 1995-570674, filed on 11 Dec 1995, now abandoned Continuation-in-part of Ser. No. US 1994-324799, filed on 18 Oct 1994, now patented, Pat. No. US 5698195, issued on 16 Dec 1997		
Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994, now patented, Pat. No. US 5656272, issued on 12 Aug 1997 Continuation-in-part of Ser. No. US 1994-192861, filed on 4 Feb 1994, now patented.		
Pat. No. US 5919452, issued on 6 Jul 1999		
Continuation-in-part of Ser. No. US 1994-192093, filed on 4 Feb 1994 Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned		
Continuation-in-part of Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned		
Continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned		
Continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned		
DOCUMENT TYPE: Utility		
FILE SEGMENT: GRANTED		
PRIMARY EXAMINER: Caputa, Anthony C.		
ASSISTANT EXAMINER: Canella, Karen		
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS: 4		
EXEMPLARY CLAIM: 1		
NUMBER OF DRAWINGS: 49 Drawing Figure(s); 37 Drawing Page(s)		
LINE COUNT: 5429		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor- α . (TNF- α .) and are useful in vivo diagnosis and therapy of a number of TNF- α -mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies.		

L22 ANSWER 10 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:136181 USPATFULL
 TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 INVENTOR(S): Fraser, Thomas, Newton, MA, United States
 Dinsmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6277372	B1	20010821
US 1995-424855		19950419 (8)
Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned		
DOCUMENT TYPE: Utility		
FILE SEGMENT: GRANTED		
PRIMARY EXAMINER: Bansal, Geetha P.		
LEGAL REPRESENTATIVE: Lahive & Cockfield LLP, Mandragouras, Esq., Amy E., Williams, Esq., Megan E.		
NUMBER OF CLAIMS: 10		
EXEMPLARY CLAIM: 1		
NUMBER OF DRAWINGS: 43 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT: 4112		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

L22 ANSWER 9 OF 50 USPATFULL (Continued)
 methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

L22 ANSWER 11 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:112500 USPATFULL
 TITLE: Leptospiral outer membranes protein, LipL46
 INVENTOR(S): Haake, David A., Culver City, CA, United States
 PATENT ASSIGNEE(S): The University of California, Oakland, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6262235	B1	20010717
US 1999-443681		19991118 (9)
Division of Ser. No. US 1998-122210, filed on 23 Jul 1998, now patented, Pat. No. US 6140083		
DOCUMENT TYPE: Utility		
FILE SEGMENT: GRANTED		
PRIMARY EXAMINER: Stucker, Jeffrey		
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.		
NUMBER OF CLAIMS: 7		
EXEMPLARY CLAIM: 1		
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT: 1578		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB An antigenic preparation is provided containing an outer membrane protein associated with pathogenic strains of Leptospira. The protein has been designated "LipL46" for "lipoprotein from Leptospira" and because the isolated polypeptide migrates to a position corresponding to a molecular weight of 46 kD in a denaturing polyacrylamide gel. The invention provides polynucleotides encoding LipL46 and antibodies that bind the protein which are useful in the diagnosis of leptospirosis. In addition, LipL46 can be used immunologically as a vaccine for spirochete-associated pathologies.		

L22 ANSWER 12 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:107439 USPATFULL
 TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 INVENTOR(S): Isaacson, Ole, Cambridge, MA, United States
 Dinsmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258353	B1	20010710
APPLICATION INFO.:	US 1995-554779		19951107 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-424851, filed on 19 Apr 1995 Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Bansal, Geetha P.		
LEGAL REPRESENTATIVE:	Lehive & Cockfield LLP, Mandragouras, Esq., Amy E., Williams, Megan E.		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	62 Drawing Figure(s); 24 Drawing Page(s)		
LINE COUNT:	5157		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

L22 ANSWER 14 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:82311 USPATFULL
 TITLE: Method and composition for reconstituting multi-epitopic antigens to initiate an immune response
 INVENTOR(S): Madiyalakan, Ragupathy, Edmonton, Canada
 Noujaim, Antoine A., Edmonton, Canada
 Baum, Richard P., Frankfurt, Germany, Federal Republic of
 Schultes, Birgit, Edmonton, Canada
 PATENT ASSIGNEE(S): Altarex Corp., Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6241985	B1	20010605
APPLICATION INFO.:	WO 9742973		19971120
	US 1998-913290		19980320 (8)
	WO 1996-18461		19960515
			19980320 PCT 371 date
			19980320 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Unger, Susan		
LEGAL REPRESENTATIVE:	Hale and Door LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1217		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.

L22 ANSWER 13 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:102965 USPATFULL
 TITLE: Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
 INVENTOR(S): Siegel, Donald L., Hatboro, PA, United States
 PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6255455	B1	20010703
APPLICATION INFO.:	US 1999-240274		19990129 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-884045, filed on 27 Jun 1997, now patented, Pat. No. US 5876925		
PRIORITY INFORMATION:	US 1998-81380		19980410 (60)
	US 1996-28550		19961011 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Celas, Bennett		
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius, L.L.P.		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 42 Drawing Page(s)		
LINE COUNT:	3849		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.

L22 ANSWER 15 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:40268 USPATFULL
 TITLE: Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 INVENTOR(S): Dinsmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6204053	B1	20010320
APPLICATION INFO.:	US 1995-424856		19950419 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
LEGAL REPRESENTATIVE:	Lehive & Cockfield, LLP		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	49 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	3891		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

L22 ANSWER 16 OF 50 USPATFULL
 ACCESSION NUMBER: 2001:14613 USPATFULL
 TITLE: Synthetic peptides for rubella vaccine
 INVENTOR(S): Chong, Pele, Richmond Hill, Canada
 Gillam, Shirley, Vancouver, Canada
 Ou, Dewi, Vancouver, Canada
 Tingle, Aubrey, Vancouver, Canada
 PATENT ASSIGNEE(S): Connaught Laboratories Limited, Toronto, Canada
 (non-U.S. corporation)

NUMBER	KIND	DATE
US 6180758	B1	20010130
US 1997-834130		19970414 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-256747, filed on 6 Oct 1994, now patented, Pat. No. US 6037448

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Stucker, Jeffrey
 LEGAL REPRESENTATIVE: Sim & McBurney
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 1559
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic peptides have an amino acids sequence corresponding to at least one antigenic determinant of at least one protein, usually

a structural protein, particularly the E1, E2 or C proteins, of rubella virus (RV), are used as is, in hybrid or chimeric tandem T-B form, in lipidated form, linked to a carrier molecule and/or polymerised to form molecular aggregates, in vaccines against rubella. Analogs of peptides which are human T-cell determinants are used to treat rubella-associated autoimmune disorders.

L22 ANSWER 18 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:146129 USPATFULL
 TITLE: Leptospiral outer membrane protein, LipL46
 INVENTOR(S): Haake, David A., Culver City, CA, United States
 PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6140083		20001031
US 1998-122210		19980723 (9)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Stucker, Jeffrey
 LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich LLP, Naile, Lisa A.
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
 LINE COUNT: 1775
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antigenic preparation is provided containing an outer membrane protein associated with pathogenic strains of Leptospira. The protein has been designated "LipL46" for "lipoprotein from Leptospira" and because the isolated polypeptide migrates to a position corresponding

to a molecular weight of 46 kD in a denaturing polyacrylamide gel. The invention provides polynucleotides encoding LipL46 and antibodies that bind the protein which are useful in the diagnosis of leptospirosis. In addition, LipL46 can be used immunologically as a vaccine for spirochete-associated pathologies.

L22 ANSWER 17 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:146162 USPATFULL
 TITLE: Isolated and modified porcine cerebral cortical cells
 INVENTOR(S): Dinsmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6140116		20001031
US 1995-551820		19951107 (8)

APPLICATION INFO.: Continuation-in-part of Ser. No. US 1995-424856, filed on 19 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-336856, filed on 8 Nov 1995, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Lankford, Jr., Leon B.
 LEGAL REPRESENTATIVE: Lohive & Cockfield, LLP, Williams, Megan E., Mandragouras, Esq., Amy E.
 NUMBER OF CLAIMS: 27
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 40 Drawing Figure(s); 21 Drawing Page(s)
 LINE COUNT: 5001
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the

cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from

a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

L22 ANSWER 19 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:114116 USPATFULL
 TITLE: Mammalian cell surface antigens; related reagents
 INVENTOR(S): Gorman, Daniel M., Newark, CA, United States
 Randall, Troy D., Saranac Lake, NY, United States
 Zlotnik, Albert, Palo Alto, CA, United States
 PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6111090		20000829
US 1997-911423		19970814 (8)

NUMBER	DATE
US 1996-23419	19960816 (60)
US 1996-27901	19961007 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Saunders, David
 ASSISTANT EXAMINER: Tung, Mary Beth
 LEGAL REPRESENTATIVE: Keleher, Gerald P., Mohan-Peterson, Sheela, Ching, Edwin P.
 NUMBER OF CLAIMS: 36
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2525
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

L22 ANSWER 20 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:67575 USPATFULL
 TITLE: Antibodies to lymphocyte activation antigens and uses therefor
 INVENTOR(S): Tedder, Thomas, Durham, NC, United States
 Zhou, Liang-Ji, Houston, TX, United States
 PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6068984		20000530
APPLICATION INFO.:	US 1998-16649		19980130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-428943, filed on 24 Apr 1995, now patented, Pat. No. US 5766570 which is a continuation of Ser. No. US 1994-233005, filed on 25 Apr 1994, now patented, Pat. No. US 5710262 which is a continuation-in-part of Ser. No. US 1992-870029, filed on 17 Apr 1992, now patented, Pat. No. US 5316920		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Saunders, David
 LEGAL REPRESENTATIVE: Weingarten, Schurgin, Gegnebin & Hayes LLP
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 17 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 1641

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HB15-related lymphocyte activation antigens, and nucleic acid sequences encoding HB15-related antigens are disclosed. Also disclosed are antibodies reactive with HB15.

L22 ANSWER 21 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:31521 USPATFULL
 TITLE: Synthetic peptides for a rubella vaccine
 INVENTOR(S): Chong, Pele, Richmond Hill, Canada
 Gillam, Shirley, Vancouver, Canada
 Ou, Dawei, Vancouver, Canada
 Tingle, Aubrey, Vancouver, Canada
 PATENT ASSIGNEE(S): Connaught Laboratories Limited, North York, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6037448		20000314
APPLICATION INFO.:	WO 9314206		19930722
	US 1994-256747		19941006 (8)
	WO 1993-CA14		19930120
			19941006 PCT 371 date
			19941006 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-1139	19920120
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Nucker, Christine M.	
ASSISTANT EXAMINER:	Stucker, Jeffrey	
LEGAL REPRESENTATIVE:	Sim & McBurney	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	2538	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic peptides have an amino acids sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the E1, E2 or C proteins, of rubella virus (RV), are used as is, in hybrid or chimeric tandem T-B form, in lipidated form, linked to a carrier molecule and/or polymerised to form molecular aggregates, in vaccines against rubella. Analogs of peptides which are human T-cell determinants are used to treat rubella-associated autoimmune disorders.

L22 ANSWER 22 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:7296 USPATFULL
 TITLE: Bovine viral diarrhea virus II vaccine and method of immunization
 INVENTOR(S): van den Hurk, Jan, Saskatoon, Canada
 Tijssen, Peter, Pointe Claire, Canada
 PATENT ASSIGNEE(S): Biostar, Inc., Saskatoon, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015795		20000118
APPLICATION INFO.:	US 1998-8722		19980119 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-445746, filed on 22 May 1995, now patented, Pat. No. US 5709865 which is a continuation-in-part of Ser. No. US 1994-337618, filed on 10 Nov 1994, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Mosher, Mary E.
 ASSISTANT EXAMINER: Salimi, Ali R.
 LEGAL REPRESENTATIVE: Sholtz, Charles K. Dehlinger & Associates
 NUMBER OF CLAIMS: 2
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 1935

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the identification of Bovine Viral Diarrhea virus group II (BVDV-II) nucleic acid sequences (e.g., gp53 sequences), to methods of using the nucleic acid sequences for detecting BVD-II virus in animal sera, to polypeptide viral antigens derived from the sequences and immunoreactive with sera from animals infected with Bovine Viral Diarrhea group II (BVD-II) virus, to polynucleotide sequences which encode these polypeptide antigens, to an expression system capable of producing the polypeptide antigens, to vaccines containing the polypeptide antigens, to methods of using the polypeptide antigens for detecting BVD-II virus antibodies in animal sera, and to antibodies directed against these polypeptide antigens.

L22 ANSWER 23 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:7195 USPATFULL
 TITLE: Method for stimulating an immune response utilizing recombinant alphavirus particles
 INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Chang, Steven M.W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015694		20000118
APPLICATION INFO.:	US 1997-931869		19970916 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Brusca, John S.
 LEGAL REPRESENTATIVE: McMasters, David D., Blackburn, Robert P.
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 35 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 10431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L22 ANSWER 24 OF 50 USPATFULL
 ACCESSION NUMBER: 2000:7187 USPATFULL
 TITLE: Eukaryotic layered vector initiation systems
 INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 Chiron Viagene, Inc., Emeryville, CA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE
 PATENT INFORMATION: US 6015686 20000118
 APPLICATION INFO.: US 1995-404796 19950315 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Ketter, James
 ASSISTANT EXAMINER: Brusca, John S.
 LEGAL REPRESENTATIVE: Seed & Berry, Kruse, Norman J., Blackburn, Robert P.
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 10466
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L22 ANSWER 26 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:117663 USPATFULL
 TITLE: HCV isolates
 INVENTOR(S): Miyamura, Tatsu, Tokyo, Japan
 Saito, Izumi, Tokyo, Japan
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 The Director General of the National Institute of Health of Japan, Tokyo, Japan (non-U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE
 PATENT INFORMATION: US 5959092 19990928
 APPLICATION INFO.: US 1995-436966 19950508 (8)
 RELATED APPLN. INFO.: Division of Ser. No. US 1994-334255, filed on 3 Nov 1994 which is a division of Ser. No. US 1994-201066, filed on 24 Feb 1994, now patented, Pat. No. US 5372928
 which is a continuation of Ser. No. US 1993-101280, filed on 2 Aug 1993, now abandoned which is a continuation of Ser. No. US 1991-637380, filed on 4 Jan 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-456142, filed on 21 Dec 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-408045, filed on 15 Sep 1989, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Knode, Marian C.
 ASSISTANT EXAMINER: Zeman, Mary K.
 LEGAL REPRESENTATIVE: Hoscheit, Dale H., Harbin, Alisa A., Blackburn, Robert P.
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 24 Drawing Figure(s); 23 Drawing Page(s)
 LINE COUNT: 2194
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1.
 Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.

L22 ANSWER 25 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:132231 USPATFULL
 TITLE: Method of eliciting anti-HIV-1 helper T cell responses
 INVENTOR(S): Walker, Bruce D., Milton, MA, United States
 PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
 NUMBER KIND DATE
 PATENT INFORMATION: US 5972339 19991026
 APPLICATION INFO.: US 1997-969721 19971113 (8)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Stucker, Jeffrey
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.
 NUMBER OF CLAIMS: 33
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 1089
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method of producing an HIV-specific helper T cell response in an animal by (1) providing a polypeptide 8 to 50 amino acid residues in length and having a helper T cell epitope of a HIV-1 p24 peptide; and (2) administering to the animal an amount of the polypeptide sufficient to produce an HIV-specific helper T cell response.

L22 ANSWER 27 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:75310 USPATFULL
 TITLE: Methods of treating TNF.alpha.-mediated disease using chimeric anti-TNF antibodies
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Dadonna, Peter, Palo Alto, CA, United States
 Ghayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Seigel, Scott, Westborough, MA, United States
 New York University, New York, NY, United States (U.S. corporation)
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE
 PATENT INFORMATION: US 5919452 19990706
 APPLICATION INFO.: US 1994-192861 19940204 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Scheiner, Toni R.
 ASSISTANT EXAMINER: Johnson, Nancy A.
 LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 48 Drawing Figure(s); 36 Drawing Page(s)
 LINE COUNT: 5351
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor-.alpha. (TNF.alpha.) or tumor necrosis factor-.beta. (TNF.beta.) and which are useful for in vivo therapy or diagnosis of TNF.alpha.-mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.

L22 ANSWER 28 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:75307 USPATFULL
 TITLE: Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
 INVENTOR(S): Dinmore, Jonathan, Brookline, MA, United States
 PATENT ASSIGNEE(S): Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919449	19990706
APPLICATION INFO.:	US 1995-454989	19950530 (8)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Christina	
ASSISTANT EXAMINER:	Nolan, Patrick J.	
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, Mandragouras, Amy E., Williams, Megan E.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	5	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1594	

AB Porcine cardiomyocytes and methods for using the cardiomyocytes to treat disorders characterized by insufficient cardiac function are described. The porcine cardiomyocytes are preferably embryonic porcine cardiomyocytes. The porcine cardiomyocytes can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine cardiomyocytes can be modified such that an antigen (e.g., an MHC class I antigen) on the cardiomyocyte surface which is capable of stimulating an immune response against the cardiomyocytes in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cardiomyocyte when introduced into the subject. In one embodiment, the porcine cardiomyocytes are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine cardiomyocytes of the present invention can be used to treat disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a xenogeneic subject by administering the cardiomyocytes to the subject.

L22 ANSWER 30 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:21887 USPATFULL
 TITLE: HCV isolates
 INVENTOR(S): Miyamura, Tetsuo, Tokyo, Japan
 Saito, Izumi, Tokyo, Japan
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 The Director General of the National Institute of Health of Japan, Tokyo, Japan (non-U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 5871903	19990216
APPLICATION INFO.:	US 1995-436965	19950508 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-334255, filed on 3 Nov 1994 which is a division of Ser. No. US 1994-201066, filed on 24 Feb 1994, now patented, Pat. No. US 5372928	

which is a continuation of Ser. No. US 1993-101280, filed on 2 Aug 1993, now abandoned which is a continuation of Ser. No. US 1991-637380, filed on 4 Jan 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-456142, filed on 21 Dec 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-408045, filed on 15 Sep 1989, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Zeman, Mary K.
 LEGAL REPRESENTATIVE: Hoscheit, Dale H., Harbin, Alisa A., Blackburn, Robert P.

NUMBER	KIND	DATE
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	2190	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.

L22 ANSWER 29 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:24779 USPATFULL
 TITLE: Hepatitis G virus and molecular cloning thereof
 INVENTOR(S): Kim, Jungshuh P., Palo alto, CA, United States
 Fry, Kirk E., Palo alto, CA, United States
 Young, Lavonne Marie, Palo alto, CA, United States
 Linnen, Jeffrey M., Foster City, CA, United States
 Wages, John, Corvallis, OR, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 5874563	19990223
APPLICATION INFO.:	US 1995-485910	19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-444733, filed on 19 May 1995 which is a continuation-in-part of Ser. No. US 1994-344271, filed on 23 Nov 1994, now abandoned And Ser. No. US 1995-389886, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-357009, filed on 16 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-329729, filed on 26 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-285558, filed on 3 Aug 1994, now abandoned And Ser. No. US 1994-285543, filed on 3 Aug 1994, now abandoned, said Ser. No. US 285558 And Ser. No. US 285543, each Ser. No. US which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, now abandoned	

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Brumback, Brenda G.
 LEGAL REPRESENTATIVE: Fabian, Gary R., Evans, Susan T., Dehlinger, Peter J.

NUMBER	KIND	DATE
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	43 Drawing Figure(s); 17 Drawing Page(s)	
LINE COUNT:	9248	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

L22 ANSWER 31 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:1766 USPATFULL
 TITLE: Hepatitis C virus isolate polypeptides
 INVENTOR(S): Miyamura, Tetsuo, Tokyo, Japan
 Saito, Izumi, Tokyo, Japan
 Houghton, Michael, Danville, CA, United States
 Weiner, Amy J., Benicia, CA, United States
 Han, Jang, Lafayette, CA, United States
 Kolberg, Janice A., Hercules, CA, United States
 Cha, Tai-An, San Ramon, CA, United States
 Irvine, Bruce D., Concord, CA, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 The Director General of the National Institute of Health of Japan, Tokyo, Japan (non-U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856437	19990105
APPLICATION INFO.:	US 1994-334255	19941103 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-201066, filed on 24 Feb 1994, now patented, Pat. No. US 5372928 which is a continuation of Ser. No. US 1993-101280, filed on 2 Aug 1993 which is a continuation of Ser. No. US 1991-637380, filed on 4 Jan 1991 which is a continuation-in-part of Ser. No. US 1989-456142, filed on 21 Dec 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-408045, filed on 15 Sep 1989, now abandoned	

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Zeman, Mary K.
 LEGAL REPRESENTATIVE: Hoscheit, Dale H., Harbin, Alisa A., Blackburn, Robert P.

NUMBER	KIND	DATE
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	2184	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.

L22 ANSWER 32 OF 50 USPATFULL
 ACCESSION NUMBER: 1999:1473 USPATFULL
 TITLE: Hepatitis G virus and molecular cloning thereof
 INVENTOR(S): Kim, Jungshuh P., Palo Alto, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Young, LaVonne Marie, Palo Alto, CA, United States
 Linnen, Jeffrey M., Foster City, CA, United States
 Wages, John, Corvallis, OR, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5856134		19990105
US 1995-461361		19950605 (8)

PATENT INFORMATION: Division of Ser. No. US 1995-444733, filed on 19 May 1995 which is a continuation-in-part of Ser. No. US 1994-344271, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-285561, filed on 3 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, now abandoned, said Ser. No. US

444733

which is a continuation-in-part of Ser. No. US 1995-389886, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-357509, filed on 16 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-329729, filed on 26 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-285558, filed on 3 Aug 1994, now abandoned And Ser. No. US 1994-285543, filed on 3 Aug 1994, now abandoned, said Ser. No. US 285558 And Ser. No. US 285543, each Ser. No. US which is a continuation-in-part of Ser. No. US 246985

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Brumback, Brenda Glass
 LEGAL REPRESENTATIVE: Fabian, Gary R., Evans, Susan T., Dehlinger, Peter J.
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 43 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 9194
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

L22 ANSWER 33 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:157144 USPATFULL
 TITLE: Hepatitis G virus and molecular cloning thereof
 INVENTOR(S): Kim, Jungshuh P., Palo Alto, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Young, LaVonne Marie, Palo Alto, CA, United States
 Linnen, Jeffrey M., Foster City, CA, United States
 Wages, John, Corvallis, OR, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5849532		19981215
US 1995-464134		19950606 (8)

PATENT INFORMATION: Division of Ser. No. US 1995-444733, filed on 19 May 1995 And a continuation-in-part of Ser. No. US 1995-389886, filed on 15 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-357509, filed on 16 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-329729, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-285558, filed on 3 Aug 1994 And Ser. No. US 1994-285543, filed on 3 Aug 1994, said Ser. No. US 285558 which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, said Ser. No. US 285543 which is a continuation-in-part of Ser. No. US 246985, said Ser. No. US 444733 which is a continuation-in-part of Ser. No. US 1994-344271, filed on 23 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-285561, filed on 3 Aug 1994 which is a continuation-in-part of Ser. No. US 246985

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Brumback, Brenda Glass
 LEGAL REPRESENTATIVE: Fabian, Gary R., Evans, Susan T., Dehlinger, Peter J.
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 41 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 9194
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

L22 ANSWER 32 OF 50 USPATFULL (Continued)

L22 ANSWER 34 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:150739 USPATFULL
 TITLE: Alphavirus vector constructs
 INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 Belli, Barbara A., San Diego, CA, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5843723		19981201
US 1996-739167		19961030 (8)

PATENT INFORMATION: Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned

US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Ketter, James
 ASSISTANT EXAMINER: Brusca, John S.
 LEGAL REPRESENTATIVE: Mc Masters, David D., Kruse, Norman J., Blackburn, Robert P.

NUMBER OF CLAIMS: 47
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 10318
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and method, for utilizing recombinant alphavirus vectors.

L22 ANSWER 35 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:147567 USPATFULL
 TITLE: Monoclonal antibody BR110 and uses thereof
 INVENTOR(S): Hellstrom, Karl Erik, Seattle, WA, United States
 Hellstrom, Ingegerd, Seattle, WA, United States
 Garrigues, Ursula, Bainbridge Island, WA, United States
 States
 McAndrew, Stephen, Newtown, PA, United States
 Marquardt, Hans, Mercer Island, WA, United States
 Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840854		19981124
APPLICATION INFO.:	US 1996-726528		19961007 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5641	19951019 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Huff, Sheila
 ASSISTANT EXAMINER: Reeves, Julie E.
 LEGAL REPRESENTATIVE: Merchant, Gould, Smith, Edell, Welter, & Schmidt
 NUMBER OF CLAIMS: 22
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1
 LINE COUNT: 1458
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides internalizing ligands (i.e., BR110 ligands) which specifically recognize and bind the BR110 antigen. After binding the antigen, the ligand and antigen form a complex. As a complex, the antigen can be detected using well known and developed methods and commercial systems.

L22 ANSWER 36 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:138443 USPATFULL
 TITLE: Glycine-containing sequences conferring invisibility to the immune system
 INVENTOR(S): Masucci, Maria G., Sollentuna, Sweden
 PATENT ASSIGNEE(S): Cobra Therapeutics, Ltd., United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5833991		19981110
APPLICATION INFO.:	US 1995-529190		19950915 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-522995, filed on 1 Sep 1995, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1995-1324	19950410

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Cunningham, Thomas M.
 ASSISTANT EXAMINER: Lubet, Martha
 LEGAL REPRESENTATIVE: Williams, Kathleen M. Banner & Witcoff, Ltd.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 2045
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for preventing undesired immune responses in which a recombinant protein is prepared which includes a glycine-containing amino acid sequence, protein substantial invisibility to the immune system.

L22 ANSWER 37 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:128099 USPATFULL
 TITLE: Hepatitis G virus and molecular cloning thereof
 INVENTOR(S): Kim, Jungsuh P., Palo Alto, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Young, LaVonne Marie, Palo Alto, CA, United States
 Linnen, Jeffrey M., Foster City, CA, United States
 Wages, John, Corvallis, OR, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824507		19981020
APPLICATION INFO.:	US 1995-444733		19950519 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-344271, filed on 23 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-285561, filed on 3 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-389886, filed on 15 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-357509, filed on 16 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-329729, filed on 26 Oct 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-285543, filed on 3 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Woodward, Michael P.
 ASSISTANT EXAMINER: Brumback, Brenda Glass
 LEGAL REPRESENTATIVE: Fabian, Gary R., Evans, Susan T., Dehlinger, Peter J.
 NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 9248
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

L22 ANSWER 38 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:119004 USPATFULL
 TITLE: Eukaryotic layered vector initiation systems
 INVENTOR(S): Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United States 92067
 Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024
 Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814482		19980929
APPLICATION INFO.:	US 1996-739158		19961030 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Ketter, James
 ASSISTANT EXAMINER: Brusca, John S.
 LEGAL REPRESENTATIVE: Seed & Berry, Kruse, Norman J., Blackburn, Robert P.
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 10431
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L22 ANSWER 39 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:91872 USPATFULL
 TITLE: Alphavirus structural protein expression cassettes
 INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States
 Polo, John M., San Diego, CA, United States
 Ibanez, Carlos E., San Diego, CA, United States
 Chang, Stephen M. W., San Diego, CA, United States
 Jolly, Douglas J., Leucadia, CA, United States
 Driver, David A., San Diego, CA, United States
 Chiron Corporation, Emeryville, CA, United States
 PATENT ASSIGNEE(S):
 (U.S. corporation)

NUMBER	KIND	DATE
US 5789245		19980804
US 1996-741881		19961030 (8)
Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Ketter, James
 ASSISTANT EXAMINER: Brusca, John S.
 LEGAL REPRESENTATIVE: McMaisters, David D., Kruse, Norman J., Blackburn, Robert P.

NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 35 Drawing Figure(s); 30 Drawing Page(s)
 LINE COUNT: 10270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

L22 ANSWER 40 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:68767 USPATFULL
 TITLE: Hepatitis G virus and molecular cloning thereof
 INVENTOR(S): Kim, Jungsuh P., Palo Alto, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Young, LaVonne Marie, Palo Alto, CA, United States
 Linnen, Jeffrey M., Foster City, CA, United States
 Wages, John, Corvallis, OR, United States
 Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5766840		19980616
US 1995-466033		19950605 (8)
Division of Ser. No. US 1995-444733, filed on 19 May 1995 And a continuation-in-part of Ser. No. US 1995-389886, filed on 15 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-357509, filed on 16 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-329729, filed on 26 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-285558, filed on 3 Aug 1994, now abandoned And Ser. No. US 1994-285543, filed on 3 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-246985, filed on 20 May 1994, now abandoned, said Ser. No. US -285558 which is a continuation-in-part of Ser. No. US -246985, said Ser. No. US -444733 which is a continuation-in-part of Ser. No. US 1994-344271, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-285561, filed on 3 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US -246985		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Knode, Marian C.
 ASSISTANT EXAMINER: Brumback, Brenda Glass
 LEGAL REPRESENTATIVE: Febian, Gary R., Evans, Susan T., Dehlinger, Peter J.
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 43 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 5791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.

L22 ANSWER 41 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:68504 USPATFULL
 TITLE: Lymphocyte activation antigens and antibodies
 INVENTOR(S): Tedder, Thomas F., Durham, NC, United States
 Zhou, Liang-Ji, Chapel Hill, NC, United States
 Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5766570		19980616
US 1995-428943		19950424 (8)
Continuation of Ser. No. US 1994-233005, filed on 24 Apr 1994, now patented, Pat. No. US 5710262 which is a continuation-in-part of Ser. No. US 1992-870029, filed on 17 Apr 1992, now patented, Pat. No. US 5316920, issued on 31 May 1994		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Hutzell, Paula K.
 ASSISTANT EXAMINER: Bakalyar, Heather A.
 LEGAL REPRESENTATIVE: Weingarten, Schurgin, Gagnebin & Hayes LLP
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 21 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 1511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HB15-related lymphocyte activation antigens, and nucleic acid sequences encoding HB15-related antigens are disclosed. Also disclosed are antibodies reactive with HB15.

L22 ANSWER 42 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:7178 USPATFULL
 TITLE: Nucleic acid encoding HB15 polypeptides
 INVENTOR(S): Tedder, Thomas F., Durham, NC, United States
 Zhou, Liang-Ji, Boston, MA, United States
 Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5710262		19980120
US 1994-233005		19940425 (8)
Continuation-in-part of Ser. No. US 1992-870029, filed on 17 Apr 1992, now patented, Pat. No. US 5316920		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Marschel, Ardin H.
 ASSISTANT EXAMINER: Riley, Jezia
 LEGAL REPRESENTATIVE: Weingarten, Schurgin, Gagnebin & Hayes LLP
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 21 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 1486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB HB15-related lymphocyte activation antigens, and nucleic acid sequences encoding HB15-related antigens are disclosed. Also disclosed are antibodies reactive with HB15.

L22 ANSWER 43 OF 50 USPATFULL
 ACCESSION NUMBER: 1998:6790 USPATFULL
 TITLE: Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53)
 INVENTOR(S): van den Hurk, Jan, Saskatoon, Canada
 Tjaseen, Peter, Pointe Claire, Canada
 PATENT ASSIGNEE(S): Biostar Inc., Saskatoon, Canada (non-U.S. corporation)

NUMBER	KIND	DATE
US 5709865		19980120
US 1995-445746		19950522 (8)

APPLICATION INFO.: Continuation-in-part of Ser. No. US 1994-337618, filed on 10 Nov 1994, now abandoned
 RELATED APPLN. INFO.: Utility
 DOCUMENT TYPE: Granted
 FILE SEGMENT: Knodes, Marian C.
 PRIMARY EXAMINER: Salimi, Ali R.
 ASSISTANT EXAMINER: Sholtz, Charles K. Dehlinger & Associates
 LEGAL REPRESENTATIVE: 4
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 13 Drawing Figure(s); 12 Drawing Page(s)
 NUMBER OF DRAWINGS: 1881
 LINE COUNT: 1881

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to the identification of Bovine Viral Diarrhea Virus group II (BVDV-II) nucleic acid sequences (e.g., gp53 sequences), to methods of using the nucleic acid sequences for detecting BVD-II virus in animal sera, to polypeptide vital antigens derived from the sequences and immunoreactive with sera from animals infected with Bovine Viral Diarrhea group II (BVDV-II) virus, to polynucleotide sequences which encode these polypeptide antigens, to an expression system capable of producing the polypeptide antigens, to vaccines containing the polypeptide antigens, to methods of using the polypeptide antigens for detecting BVD-II virus antibodies in animal sera, and to antibodies directed against these polypeptide antigens.

L22 ANSWER 45 OF 50 USPATFULL
 ACCESSION NUMBER: 97:70718 USPATFULL
 TITLE: Methods of treating TNF- α -mediated Crohn's disease using chimeric anti-TNF antibodies
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Dadonna, Peter, Palo Alto, CA, United States
 Ghayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott A., Westborough, MA, United States
 PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5656272		19970812
US 1994-192102		19940204 (8)

APPLICATION INFO.: Continuation-in-part of Ser. No. US 1993-10406, filed on 26 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned
 RELATED APPLN. INFO.: Utility
 DOCUMENT TYPE: Granted
 FILE SEGMENT: Feisee, Lila
 PRIMARY EXAMINER: Lucas, John
 ASSISTANT EXAMINER: Hamilton, Brook, Smith & Reynolds, P.C.
 LEGAL REPRESENTATIVE: 7
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 48 Drawing Figure(s); 36 Drawing Page(s)
 NUMBER OF DRAWINGS: 5251
 LINE COUNT: 5251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor- α (TNF- α) and are useful in vivo for diagnosis and therapy of a number of TNF- α -mediated pathologies and conditions, including Crohn's disease, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

L22 ANSWER 44 OF 50 USPATFULL
 ACCESSION NUMBER: 97:117693 USPATFULL
 TITLE: Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
 INVENTOR(S): Le, Junming, Jackson Heights, NY, United States
 Vilcek, Jan, New York, NY, United States
 Daddona, Peter, Menlo Park, CA, United States
 Ghayeb, John, Thorndale, PA, United States
 Knight, David, Berwyn, PA, United States
 Siegel, Scott, Westborough, MA, United States
 PATENT ASSIGNEE(S): New York University Medical Center, New York, NY, United States (U.S. corporation)
 Centocor, Inc., Malvern, PA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5698195		19971216
US 1994-324799		19941018 (8)

APPLICATION INFO.: Continuation-in-part of Ser. No. US 1994-192102, filed on 4 Feb 1994 Ser. No. US 1994-192061, filed on 4 Feb 1994, now abandoned And Ser. No. US 1994-192093, filed on 4 Feb 1994, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-10406, filed on 29 Jan 1993, now abandoned And Ser. No. US 1993-13413, filed on 2 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-943852, filed on 11 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-853606, filed on 18 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-670827, filed on 18 Mar 1991, now abandoned
 RELATED APPLN. INFO.: Utility
 DOCUMENT TYPE: Granted
 FILE SEGMENT: Feisee, Lila
 PRIMARY EXAMINER: Lucas, John
 ASSISTANT EXAMINER: Hamilton, Brook, Smith & Reynolds, P.C.
 LEGAL REPRESENTATIVE: 16
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 33 Drawing Figure(s); 36 Drawing Page(s)
 NUMBER OF DRAWINGS: 5887
 LINE COUNT: 5887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor- α (TNF- α) and are useful in vivo for diagnosis and therapy of a number of TNF- α -mediated pathologies and conditions, including rheumatoid arthritis as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.

L22 ANSWER 46 OF 50 USPATFULL
 ACCESSION NUMBER: 97:2475 USPATFULL
 TITLE: T cell receptor peptides as therapeutics for immune-related disease
 INVENTOR(S): Vandenbark, Arthur A., Portland, OR, United States
 PATENT ASSIGNEE(S): Connective Therapeutics, Inc., Palo Alto, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5614192		19970325
US 1993-59020		19930316 (8)

APPLICATION INFO.: Continuation of Ser. No. US 1991-735612, filed on 16 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-708022, filed on 31 May 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-554529, filed on 19 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467577, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-382804, filed on 19 Jul 1989, now abandoned
 RELATED APPLN. INFO.: Utility
 DOCUMENT TYPE: Granted
 FILE SEGMENT: Cunningham, Thomas M.
 PRIMARY EXAMINER: Lowin, David A., Warburg, Richard J. Lyon & Lyon
 LEGAL REPRESENTATIVE: 56
 NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 47 Drawing Figure(s); 27 Drawing Page(s)
 NUMBER OF DRAWINGS: 5870
 LINE COUNT: 5870

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Peptides and pharmaceutical compositions comprising immunogenic peptides of a marker T cell receptor (TCR) characteristic of an immune-related disease, capable of preventing, suppressing, or treating the disease, are disclosed. In a preferred embodiment, the amino acid sequence of the peptide corresponds to at least part of the second complementarity determining region (CDR2) of the TCR. Antibodies and/or T cells immunologically reactive to the TCR peptide capable of preventing, suppressing, or treating an immune-related disease by passive transfer are also disclosed.

L22 ANSWER 47 OF 50 USPATFULL
 ACCESSION NUMBER: 94:108852 USPATFULL
 TITLE: Hepatitis C virus isolates
 INVENTOR(S): Miyamura, Tatsuo, Tokyo, Japan
 Saito, Izumi, Tokyo, Japan
 Houghton, Michael, Danville, CA, United States
 Weiner, Amy J., Benicia, CA, United States
 Han, Jang, Lafayette, CA, United States
 Kolberg, Janice A., Hercules, CA, United States
 Cha, Tai-An, San Ramon, CA, United States
 Irvine, Bruce D., Concord, CA, United States
 Chiron Corporation, Emeryville, CA, United States
 corporation)
 The Director General of the National Institute of
 Health of Japan, Tokyo, Japan (non-U.S. corporation)

NUMBER	KIND	DATE
US 5372928		19941213
US 1994-201066		19940224 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-101280, filed on 2 Aug
 1993, now abandoned which is a continuation of Ser.
 No. US 1991-637380, filed on 4 Jan 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-456142, filed on 21 Dec 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-408045, filed on 15 Sep 1989, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Wax, Robert A.
 ASSISTANT EXAMINER: Bugalsky, Gabriele E.
 LEGAL REPRESENTATIVE: Goldman, Kenneth M., McClung, Barbara G., Blackburn, Robert P.

NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 24 Drawing Figure(s); 23 Drawing Page(s)
 LINE COUNT: 2182

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1.
 Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.

L22 ANSWER 49 OF 50 USPATFULL
 ACCESSION NUMBER: 89:90797 USPATFULL
 TITLE: Enhanced production of antibodies utilizing insolubilized immune complexes
 INVENTOR(S): Morgan, Jr., Alton C., Edmonds, WA, United States
 Woodhouse, Clive S., Seattle, WA, United States
 McIntyre, Robert F., Seattle, WA, United States
 NeorX Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 4879225		19891107
US 1987-24632		19870311 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-876828, filed on 20 Jun 1986

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Nucker, Christine M.
 ASSISTANT EXAMINER: Krupen, Karen I.
 LEGAL REPRESENTATIVE: Leith, Debra K.

NUMBER OF CLAIMS: 58
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 4 Drawing Page(s)
 LINE COUNT: 1058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for enhancing production of antibodies through immunization with insolubilized immune complexes is disclosed. Purified antigen or heterogeneous antigen mixtures may be combined with polyclonal or monoclonal antibody and the resultant complex bound to insolubilized protein A to form insolubilized immune complexes.
 Methods for improving the immunogenicity of a soluble antigen and for producing monoclonal anti-idiotypic antibodies are also disclosed. Monoclonal antibodies that are specific for a distinct, as yet unrecognized epitope may be produced by another disclosed method. Insolubilized immune complexes, comprising antigen and antibody that is either directly linked to Sepharose-RTM, or absorbed onto insolubilized protein A, and immunosorbents, comprising antibody absorbed onto insolubilized protein A, are also disclosed.

L22 ANSWER 48 OF 50 USPATFULL
 ACCESSION NUMBER: 92:7286 USPATFULL
 TITLE: Enhanced production of antibodies utilizing insolubilized immune complexes
 INVENTOR(S): Morgan, Jr., A. Charles, Edmonds, WA, United States
 Woodhouse, Clive S., Seattle, WA, United States
 McIntyre, Robert F., Seattle, WA, United States
 NeorX Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5084396		19920128
US 1990-579627		19900907 (7)

DISCLAIMER DATE: 20061107
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-391286, filed on 8 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-24632, filed on 11 Mar 1987, now patented, Pat. No. US 4879225 which is a continuation-in-part of Ser. No. US 1986-876828, filed on 20 Jun 1986, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Wax, Robert A.
 ASSISTANT EXAMINER: Sisson, Bradley L.
 LEGAL REPRESENTATIVE: Leith, Debra K.

NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 1122

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method for enhancing production of antibodies through immunization with insolubilized immune complexes is disclosed. Purified antigen or heterogeneous antigen mixtures may be combined with polyclonal or monoclonal antibody and the resultant complex bound to an insolubilized matrix to form insolubilized immune complexes.
 Methods for improving the immunogenicity of a soluble antigen and for producing monoclonal anti-idiotypic antibodies are also disclosed. Monoclonal antibodies that are specific for a distinct, as yet unrecognized epitope may be produced by another disclosed method. Insolubilized immune complexes, comprising antigen and antibody that is either directly linked to Sepharose-RTM, or absorbed onto insolubilized protein A, and immunosorbents, comprising antibody absorbed onto insolubilized protein A, are also disclosed.

L22 ANSWER 50 OF 50 USPATFULL
 ACCESSION NUMBER: 89:72973 USPATFULL
 TITLE: Method and system for administering therapeutic and diagnostic agents
 INVENTOR(S): Goodwin, David A., Atherton, CA, United States
 Meares, Claude, Davis, CA, United States
 McCall, Michael, Vacaville, CA, United States
 The Board of Trustees of Leland Stanford Jr. Univ., Stanford, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 4863713		19890905
US 1986-877327		19860623 (6)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Maples, John S.
 LEGAL REPRESENTATIVE: Dehlinger, Peter J.

NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1, 14
 NUMBER OF DRAWINGS: 3 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 1142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method and system for localizing a diagnostic or therapeutic agent to an internal target site. The system includes (1) an epitopic compound, (2) a binding protein which is effective to bind specifically with the compound and capable of localizing selectively at the target tissue, when administered parenterally, and (3) a clearing agent which can bind to and cross-link the binding protein, to form a protein aggregate which is readily cleared from the subject's bloodstream. In practicing the method of the invention, the binding protein is administered to the subject parenterally, and allowed to localize at the target site, typically within 1-4 days. This is followed by a chase with the clearing agent to remove circulating, but not target-localized binding protein. When the epitopic compound is administered, binding of the compound to the localized binding protein, and rapid clearance of unbound compound by the kidneys, results in selective localization of the compound at the target site.

09/597,580

Page 34

=> s l18 and first(w)conjugate?

L23 38 L18 AND FIRST(W) CONJUGATE?

=> dup rem l23

PROCESSING COMPLETED FOR L23

L24 38 DUP REM L23 (0 DUPLICATES REMOVED)

=> d ibib ab 1-

YOU HAVE REQUESTED DATA FROM 38 ANSWERS - CONTINUE? Y/(N):y

L24 ANSWER 1 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:152673 USPATFULL
 TITLE: Methods for detecting and identifying single molecules
 INVENTOR(S): Cubicciotti, Roger S., Montclair, NJ, United States
 PATENT ASSIGNEE(S): Molecular Machines, Inc., Montclair, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287765	B1	20010911
APPLICATION INFO.:	US 1998-81930		19980520 (9)
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Fredman, Jeffrey		
LEGAL REPRESENTATIVE:	Licata & Tyrrell P.C.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	15456		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Multimolecular devices and drug delivery systems prepared from synthetic heteropolymers, heteropolymeric discrete structures, multivalent heteropolymeric hybrid structures, aptameric multimolecular devices, multivalent imprints, tethered specific recognition devices, paired specific recognition devices, nonaptameric multimolecular devices and immobilized multimolecular structures are provided, including molecular adsorbents and multimolecular adherents, adhesives, transducers, switches, sensors and delivery systems. Methods for selecting single synthetic nucleotides, shape-specific probes and specifically attractive surfaces for use in these multimolecular devices are also provided. In addition, paired nucleotide-nonnucleotide mapping libraries for transposition of selected populations of selected nonoligonucleotide molecules into selected populations of replicatable nucleotide sequences are described.

L24 ANSWER 2 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:152454 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287536	B1	20010911
APPLICATION INFO.:	US 1997-788339		19970127 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-122979, filed on 16 Sep 1993, now patented, Pat. No. US 5630996 Continuation of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, now abandoned Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	SEED Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	4802		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

L24 ANSWER 3 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:55447 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Meyer, Damon L., Bellevue, WA, United States
 Mallett, Robert W., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6217869	B1	20010417
APPLICATION INFO.:	US 1997-926336		19970905 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned Continuation-in-part of Ser. No. 163188, now abandoned Continuation-in-part of Ser. No. US 1992-395381, filed on 23 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	UTILITY		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	6397		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.

L24 ANSWER 4 OF 38 USPATFULL
 ACCESSION NUMBER: 2001:4719 USPATFULL
 TITLE: Cluster clearing agents
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172045	B1	20010109
APPLICATION INFO.:	US 1996-659761		19960606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-350551, filed on 7 Dec 1994, now patented, Pat. No. US 6075010		
DOCUMENT TYPE:	PATENT		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3400		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.

L24 ANSWER 5 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:153836 USPATFULL
 TITLE: Nucleic acid ligand complexes
 INVENTOR(S): Gold, Larry, Boulder, CO, United States
 Schmidt, Paul G, Niwot, CO, United States
 Janjic, Nebojsa, Boulder, CO, United States
 PATENT ASSIGNEE(S): NeXtar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6147204		20001114
WO 9634876		19961107
US 1997-945604		19971028 (8)
WO 1996-US6171		19960502
		19971028 PCT 371 date
		19971028 PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-434465, filed on 4 May 1995, now patented, Pat. No. US 6011020 And a continuation-in-part of Ser. No. US 1995-464443, filed on 5 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096

which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Zitomer, Stephanie
 LEGAL REPRESENTATIVE: Swanson & Bratschun, L.L.C.
 NUMBER OF CLAIMS: 39
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 36 Drawing Figure(s); 34 Drawing Page(s)
 LINE COUNT: 2756
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

L24 ANSWER 7 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:77028 USPATFULL
 TITLE: Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
 INVENTOR(S): Lipkin, W. Ian, Laguna Beach, CA, United States
 Briese, Thomas, Laguna Beach, CA, United States
 Kliche, Stefanie, Berlin, Germany, Federal Republic of
 Schneider, Patrick A., Irvine, CA, United States
 Stitz, Lothar, Wetzlar, Germany, Federal Republic of
 Schneemann, Annette, San Diego, CA, United States
 PATENT ASSIGNEE(S): Regents of the University of California, Alameda, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6077510		20000620
US 1996-582776		19960104 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-434831, filed on 4 May 1995 which is a continuation-in-part of Ser. No. US 1995-369822, filed on 6 Jan 1995, now patented, Pat. No. US 6015660

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Mosher, Mary E.
 LEGAL REPRESENTATIVE: Fulbright & Jaworski, LLP
 NUMBER OF CLAIMS: 19
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 25 Drawing Figure(s); 33 Drawing Page(s)
 LINE COUNT: 5206
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention presents: genomic nucleotide sequence of Borna disease virus, nucleotide and amino acid sequences of Borna disease virus proteins, recombinant viral proteins, vectors and cells containing the sequences or encoding the proteins, ligand binding to these proteins such as antibodies, and the diagnostic and therapeutic uses of the foregoing.

L24 ANSWER 6 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:117286 USPATFULL
 TITLE: Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
 INVENTOR(S): Lipkin, W. Ian, Laguna Beach, CA, United States
 Briese, Thomas, Laguna Beach, CA, United States
 Kliche, Stefanie, Irvine, CA, United States
 Schneider, Patrick A., Irvine, CA, United States
 Stitz, Lothar, Wetzlar, Germany, Federal Republic of
 Schneemann, Anette, Santa Ana, CA, United States
 The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6113905		20000905
US 1995-434831		19950502 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-369822, filed on 6 Jan 1995, now patented, Pat. No. US 6015660

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Mosher, Mary E.
 LEGAL REPRESENTATIVE: Fulbright & Jaworski LLP
 NUMBER OF CLAIMS: 19
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 53 Drawing Figure(s); 32 Drawing Page(s)
 LINE COUNT: 5016
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention presents: genomic nucleotide sequence of Borna disease virus, nucleotide and amino acid sequences of Borna disease virus proteins, recombinant viral proteins, vectors and cells containing the sequences or encoding the proteins, ligand binding to these proteins such as antibodies, and the diagnostic and therapeutic uses of the foregoing.

L24 ANSWER 8 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:77017 USPATFULL
 TITLE: Targeted combination immunotherapy of cancer
 INVENTOR(S): Griffiths, Gary L., Morristown, NJ, United States
 Hansen, Hans J., Mystic Island, NJ, United States
 Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6077499		20000620
US 1998-184950		19981103 (9)

NUMBER	DATE
US 1996-17011	19960503 (60)

PRIORITY INFORMATION: US 1996-17011 19960503 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Dees, Jose' G.
 ASSISTANT EXAMINER: Jones, Dameron
 LEGAL REPRESENTATIVE: Foley & Lardner
 NUMBER OF CLAIMS: 37
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 1074
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions, methods and kits for effecting therapy of a tumor in a patient. The compositions comprise (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor; (B) optionally, a clearing composition; and (C) a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent. The methods comprise sequentially administering (A), (B), and (C) to a patient. The kits comprise (A), (B), and (C) in separate containers.

L24 ANSWER 9 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:74275 USPATFULL
 TITLE: Small molecular weight ligand-hexose containing clearing agents
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6075010		20000613
US 1994-350551		19941207 (s)

PATENT INFORMATION: Continuation-in-part of Ser. No. US 1993-163184, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Duffy, Patricia A.
 LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group LLC
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 31 Drawing Figure(s); 20 Drawing Page(s)
 LINE COUNT: 5359
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Small molecule weight clearing agents containing ligands such as biotin or biotin analogs and hexose residue, in particular galactose or N-acetyl galactosamine residues are taught. These clearing agents effectively clear anti-ligand containing conjugates in vivo via hepatocyte receptor mediated clearance mechanisms.

L24 ANSWER 10 OF 38 USPATFULL (Continued)
 prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

L24 ANSWER 10 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:61575 USPATFULL
 TITLE: Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting
 INVENTOR(S): Yatvin, Milton B., Portland, OR, United States
 Stowell, Michael H B, Fulbourn, United Kingdom
 Gallicchio, Vincent S., Lexington, KY, United States
 Meredith, Michael J., Lake Oswego, OR, United States
 PATENT ASSIGNEE(S): Oregon Health Sciences University, Portland, OR, States (U.S. corporation)

NUMBER	KIND	DATE
US 6063759		20000516
US 1998-60011		19980414 (s)

PATENT INFORMATION: Continuation of Ser. No. US 1996-691891, filed on 1 Aug 1996, now patented, Pat. No. US 5840674 which is a continuation of Ser. No. US 1995-441770, filed on 16 May 1995, now patented, Pat. No. US 5543391 which is a continuation of Ser. No. US 1994-246941, filed on 19 May 1994, now patented, Pat. No. US 5543390 which is a continuation-in-part of Ser. No. US 1993-142771, filed on 26 Oct 1993, now patented, Pat. No. US 5543389

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Naff, David M.
 LEGAL REPRESENTATIVE: McDonnell Boehnen Hulbert & Berghoff
 NUMBER OF CLAIMS: 69
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 2237
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or

L24 ANSWER 11 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:46887 USPATFULL
 TITLE: Compositions for targeting the vasculature of solid tumors
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
 Burrows, Francis J., San Diego, CA, United States
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6051230		20000418
US 1995-457869		19950601 (s)

PATENT INFORMATION: Division of Ser. No. US 1994-350212, filed on 5 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994, now patented, Pat. No. US 5855866 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Hutzell, Paula K.
 ASSISTANT EXAMINER: Bansal, Geetha
 LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
 NUMBER OF CLAIMS: 61
 EXEMPLARY CLAIM: 1, 11, 40
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 25 Drawing Page(s)
 LINE COUNT: 6124
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.

L24 ANSWER 12 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:34536 USPATFULL
 TITLE: Ligand growth factor gp30 that binds to the erbB-2 receptor protein and induces cellular responses
 INVENTOR(S): Lippman, Marc E., Bethesda, MD, United States
 Lupu, Ruth, Gaithersburg, MD, United States
 PATENT ASSIGNEE(S): Georgetown University, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040290		20000321
APPLICATION INFO.:	US 1996-703089		19960826 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-96277, filed on 26 Jul 1993, now patented, Pat. No. US 5578482 which is a continuation-in-part of Ser. No. US 1992-875788, filed on 29 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-640497, filed on 14 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-917988, filed on 24 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-872114, filed on 22 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-528438, filed on 25 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kemmerer, Elizabeth		
ASSISTANT EXAMINER:	Kaufman, Claire M.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	45 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	3759		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.

L24 ANSWER 14 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:7398 USPATFULL
 TITLE: Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Kasina, Sudhakar, Kirkland, WA, United States
 Reno, John M., Brier, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015897		20000118
APPLICATION INFO.:	US 1996-645211		19960513 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Christina Y.		
ASSISTANT EXAMINER:	Gambel, Phillip		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	6303		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl DOTA is disclosed.

L24 ANSWER 13 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:15742 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Gustavson, Linda M., Seattle, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Su, Pu-Min, Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6022966		20000208
APPLICATION INFO.:	US 1993-156565		19931122 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, now patented, Pat. No. WO 5608060 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cunningham, Thomas M.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	4010		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

L24 ANSWER 15 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:7161 USPATFULL
 TITLE: Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
 INVENTOR(S): Lipkin, W. Ian, Laguna Beach, CA, United States
 Briese, Thomas, Laguna Beach, CA, United States
 Kliche, Stefanie, Irvine, CA, United States
 Schneider, Patrick A., Irvine, CA, United States
 Stitz, Lothar, Wetzlar, Germany, Federal Republic of
 Schneemann, Anette, Santa Ana, CA, United States
 The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015660		20000118
APPLICATION INFO.:	US 1995-369822		19950106 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Mosher, Mary E.		
LEGAL REPRESENTATIVE:	Margaret Churchill Fulbright & Jaworski		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	4627		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention presents: genomic nucleotide sequence of Borna disease virus, nucleotide and amino acid sequences of Borna disease virus proteins, recombinant viral proteins, vectors and cells containing the sequences or encoding the proteins, ligand binding to these proteins such as antibodies, and the diagnostic and therapeutic uses of the foregoing.

L24 ANSWER 16 OF 38 USPATFULL
 ACCESSION NUMBER: 2000:1863 USPATFULL
 TITLE: Nucleic acid ligand complexes
 INVENTOR(S): Gold, Larry, Boulder, CO, United States
 Schmidt, Paul G., San Marino, CA, United States
 Janjic, Nebojsa, Boulder, CO, United States
 PATENT ASSIGNEE(S): NeXtar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6011020		20000104
US 1995-434465		19950504 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-234997, filed on 28 Apr 1994, now patented, Pat. No. US 5683867 And Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Zitomer, Stephanie
 LEGAL REPRESENTATIVE: Swanson & Bratechun LLC
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 15 Drawing Page(s)
 LINE COUNT: 2241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

L24 ANSWER 18 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:146525 USPATFULL
 TITLE: Methods of using hepatic-directed compounds in pretargeting strategies
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5985826		19991116
US 1997-808024		19970303 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-351651, filed on 7 Dec 1994

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Russell, Jeffrey E.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 2566

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Hepatic-directed compounds, reagents useful in making such compounds and associated methods and compositions are disclosed. Hepatic-directed compounds are processed by metabolic mechanisms, which generally differ in degree or in kind from the metabolic mechanisms encountered by compounds which are not so directed. Hepatic-directed compounds useful in the methods disclosed include a hexose cluster characterized by multiple hexose residues connected in an iteratively branched configuration. In one embodiment, the hexose cluster comprises at least four hexose residues with each branch of the configuration having two prongs. In another embodiment, the hexose cluster comprises at least nine hexose residues with each branch of the configuration having three prongs.

L24 ANSWER 17 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:159997 USPATFULL
 TITLE: Compounds that bind bacterial pili
 INVENTOR(S): Shekhani, Mohammed Saleh, Madison, WI, United States
 Firca, Joseph R., Vernon Hills, IL, United States
 Anderson, Byron, Morton Grove, IL, United States
 PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5998381		19991207
US 1996-760903		19961206 (8)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Peselev, Elli
 LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 5
 NUMBER OF DRAWINGS: 23 Drawing Figure(s); 25 Drawing Page(s)
 LINE COUNT: 6570

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Diagnostics and treatments for bacterial infection are disclosed. The treatments prevent bacteria from adhering to host cells by interfering with the binding of the bacteria to cell receptors. Compounds that inhibit bacterial adherence to cells are engineered to be readily modified for best efficacy with different modes of treatment. The compounds can be readily modified for use to identify bacteria according to their cell binding specificities.

L24 ANSWER 19 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:136685 USPATFULL
 TITLE: Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
 INVENTOR(S): Fritzberg, Alan R., Edmonds, WA, United States
 Abrams, Paul G., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Graves, Scott S., Monroe, WA, United States
 Kasina, Sudhakar, Kirkland, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5976535		19991102
US 1995-468513		19950606 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5208342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Cunningham, Thomas M.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 4278

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.

L24 ANSWER 20 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:121326 USPATFULL
 TITLE: Methods and compositions for
 targeting selectins
 INVENTOR(S): Hallahan, Dennis E., Park Ridge, IL, United States
 Weichselbaum, Ralph R., Chicago, IL, United States
 PATENT ASSIGNEE(S): Arch Development Corporation, Chicago, IL, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962424		19991005
APPLICATION INFO.:	US 1995-392541		19950221 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Campbell, Bruce R.		
ASSISTANT EXAMINER:	Nguyen, Dave Trong		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	3471		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are a variety of compositions and methods for use in specifically targeting the L-selectin or preferably, the E-selectin marker following its cell surface induction, e.g., using ionizing radiation, in tumor vasculature endothelial cells. The compositions and methods described are suitable for use in the delivery of selected agents to tumor vasculature, as may be used in the diagnosis and therapy of solid tumors.

L24 ANSWER 21 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:116947 USPATFULL
 TITLE: Method for preparing radionuclide-labeled chelating
 agent-ligand complexes
 INVENTOR(S): Meares, Claude F., Davis, CA, United States
 Li, Min, Davis, CA, United States
 DeNardo, Sally J., El Macero, CA, United States
 PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
 CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5958374		19990928
APPLICATION INFO.:	US 1996-767702		19961217 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-218591, filed on 28 Mar 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Hartley, Michael G.		
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	766		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Radionuclide-labeled chelating agent-ligand complexes that are useful in medical diagnosis or therapy are prepared by reacting a radionuclide, such as .sup.90 Y or .sup.111 In, with a polyfunctional chelating agent to form a radionuclide chelate that is electrically neutral; purifying the chelate by anion exchange chromatography; and reacting the purified chelate with a targeting molecule, such as a monoclonal antibody, to form the complex.

L24 ANSWER 22 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:37255 USPATFULL
 TITLE: Hepatic-directed compounds and reagents for
 preparation thereof
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5886143		19990323
APPLICATION INFO.:	US 1994-351651		19941207 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2485		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hepatic-directed compounds, reagents useful in making such compounds and associated methods and compositions are discussed. Hepatic-directed compounds are processed by metabolic mechanisms, which generally differ in degree or in kind from the metabolic mechanisms encountered by compounds which are not so directed. Reagents useful in the preparation of hepatic-directed compounds include a hexose cluster characterized by multiple hexose residues connected in an iteratively branched configuration. In one embodiment, the hexose cluster comprises at least four hexose residues with each branch of the configuration having two prongs. In another embodiment, the hexose cluster comprises at least nine hexose residues with each branch of the configuration having three prongs.

L24 ANSWER 23 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:19279 USPATFULL
 TITLE: Antibodies to ligand growth factors
 INVENTOR(S): Lippman, Marc E., 8004 Herb Farm Dr., Bethesda, MD,
 United States 20817
 Lupu, Ruth, 181 Lazy Hollow Dr., Gaithersburg, MD,
 United States 20878

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869618		19990209
APPLICATION INFO.:	US 1995-550815		19951031 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-96277, filed on 26 Jul 1993, now patented, Pat. No. US 5578482 which is a continuation-in-part of Ser. No. US 1992-875788, filed on 29 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-640497, filed on 14 Jan 1991, now abandoned And Ser. No. US 1992-917988, filed on 24 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-872114, filed on 22 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-528438, filed on 25 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Scheiner, Toni R.		
ASSISTANT EXAMINER:	Johnson, Nancy A.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	43 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	3698		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.

L24 ANSWER 24 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:4337 USPATFULL
 TITLE: Bio-oligomer libraries and a method of use thereof
 INVENTOR(S): Lam, Kit Sang, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Salmon, Sydney E., Tucson, AZ, United States
 States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5858670		19990112
APPLICATION INFO.:	US 1996-735623		19961023 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-717454, filed on 19 Jun 1991, now patented, Pat. No. US 5650489 which is a continuation-in-part of Ser. No. US 1990-546845, filed on 2 Jul 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Sisson, Bradley L.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	2915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention provides a library of bio-oligomers of defined size and known composition, in which the library contains all of the possible sequences of the bio-oligomers, and a method of synthesis thereof. The bio-oligomers of the library may be peptides, nucleic acids, or a combination of the foregoing. The instant invention also provides methods to identify bio-oligomers from a library that demonstrate desired characteristics such as binding, bioactivity and catalytic activity. Thus the instant invention provides a unique and powerful method to identify a useful bio-oligomer sequences from a library more quickly than current state-of-the-art technology allows. Effector molecules for use in treatment or diagnosis of disease are also provided.

L24 ANSWER 25 OF 38 USPATFULL (Continued)
 drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs or agents covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs or agents to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antiviral and antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Also provided are nonporous microparticles coated with an antiviral or antimicrobial drug and further coated wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combating and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.

L24 ANSWER 25 OF 38 USPATFULL
 ACCESSION NUMBER: 1999:147392 USPATFULL
 TITLE: Covalent microparticle-drug conjugates for biological targeting
 INVENTOR(S): Yatvin, Milton B., Portland, OR, United States
 Stowell, Michael H. B., Pasadena, CA, United States
 Gallicchio, Vincent S., Lexington, KY, United States
 Meredith, Michael J., Lake Oswego, OR, United States
 Oregon Health Sciences University, Portland, OR, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840674		19981124
APPLICATION INFO.:	US 1996-691891		19960801 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-441770, filed on 16 May 1995, now patented, Pat. No. US 5543391, issued on 6 Aug 1996 And Ser. No. US 1994-246941, filed on 19		

May 1994, now patented, Pat. No. US 5543390, issued on 6 Aug 1996 which is a continuation-in-part of Ser. No. 1993-142771, filed on 26 Oct 1993, now patented, Pat. No. US 5543389, issued on 6 Aug 1996 which is a continuation-in-part of Ser. No. US 1992-911209, filed on 9 Jul 1992, now patented, Pat. No. US 5256641, issued on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1990-607982, filed on 1 Nov 1990, now patented, Pat. No. US 5149794, issued on 22 Sep 1992

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Rollins, John W.
 LEGAL REPRESENTATIVE: McDonnell, Boehnen, Hulbert & Berghoff
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 1708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antiviral and antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted

L24 ANSWER 26 OF 38 USPATFULL
 ACCESSION NUMBER: 97:64088 USPATFULL
 TITLE: Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
 INVENTOR(S): Lam, Kit Sang, Tucson, AZ, United States
 Salmon, Sydney E., Tucson, AZ, United States
 The Arizona Board of Regents, Tucson, AZ, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650489		19970722
APPLICATION INFO.:	US 1991-717454		19910619 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-546845, filed on 2 Jul 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jones, W. Gary		
ASSISTANT EXAMINER:	Sisson, Bradley L.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	2923		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention provides a library of bio-oligomers of defined size and known composition, in which the library contains all of the possible sequences of the bio-oligomers, and a method of synthesis thereof. The bio-oligomers of the library may be peptides, nucleic acids, or a combination of the foregoing. The instant invention also provides methods to identify bio-oligomers from a library that demonstrate desired characteristics such as binding, bioactivity and catalytic activity. Thus the instant invention provides a unique and powerful method to identify a useful bio-oligomer sequences from a library more quickly than current state-of-the-art technology allows. Effector molecules for use in treatment or diagnosis of disease are also provided.

L24 ANSWER 27 OF 38 USPATFULL
 ACCESSION NUMBER: 97:42628 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5630996		19970520
APPLICATION INFO.:	US 1993-122979		19930916 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned ,		

each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 4768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well

as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

L24 ANSWER 28 OF 38 USPATFULL
 ACCESSION NUMBER: 97:36156 USPATFULL
 TITLE: Clearing agents useful in pretargeting methods
 INVENTOR(S): Anworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624896		19970429
APPLICATION INFO.:	US 1995-462765		19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-163184, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented,		

Pat. No. US 5283342
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 1943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel clearing agents are provided which comprise biotin analog containing clearance-directing moieties. Preferably such clearance-directing moieties endogenously contain or a rederivatized to expose galactose and/or mannose residues.

L24 ANSWER 29 OF 38 USPATFULL
 ACCESSION NUMBER: 96:108852 USPATFULL
 TITLE: Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
 INVENTOR(S): Lippman, Marc E., Bethesda, MD, United States
 Lupu, Ruth, Gaithersburg, MD, United States
 PATENT ASSIGNEE(S): Georgetown University, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578482		19961126
APPLICATION INFO.:	US 1993-96277		19930726 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-875788, filed on 29 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-640497, filed on 14 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-917988, filed on 24 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-872114, filed on 22 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-528438, filed on 25 May 1990, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Kim, Ph.D., Kay K. A.
 LEGAL REPRESENTATIVE: Banner & Allegrretti, Ltd.
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 43 Drawing Figure(s); 23 Drawing Page(s)
 LINE COUNT: 3669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.

A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 kDa glycoprotein effective to inhibit the growth of said cells.

L24 ANSWER 30 OF 38 USPATFULL
 ACCESSION NUMBER: 96:108662 USPATFULL
 TITLE: Three-step pretargeting methods using improved biotin-active agent
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Reno, John M., Brier, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5578287		19961126
APPLICATION INFO.:	US 1993-156614		19931123 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 2318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

L24 ANSWER 31 OF 38 USPATFULL
 ACCESSION NUMBER: 96:72966 USPATFULL
 TITLE: Conjugates for the prevention and treatment of sepsis
 INVENTOR(S): Carroll, Sean B., Cottage Grove, WI, United States
 Firca, Joseph R., Vernon Hills, IL, United States
 Pugh, Charles, Madison, WI, United States
 Padhye, Nisha V., Madison, WI, United States
 PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545721		19960813
APPLICATION INFO.:	US 1993-169701		19931217 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995388, filed on 21 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Christine Y.		
ASSISTANT EXAMINER:	Eisenschent, Frank C.		
LEGAL REPRESENTATIVE:	Medlen & Carroll		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	4769		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided. Conjugates and methods of making conjugates for the prevention and treatment of sepsis are described.

L24 ANSWER 32 OF 38 USPATFULL
 ACCESSION NUMBER: 96:70431 USPATFULL
 TITLE: Covalent microparticle-drug conjugates for biological targeting
 INVENTOR(S): Yatvin, Milton B., Portland, OR, United States
 Stowell, Michael H. B., Pasadena, CA, United States
 Gallicchio, Vincent S., Lexington, KY, United States
 Meredith, Michael J., Lake Oswego, OR, United States
 PATENT ASSIGNEE(S): State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University, Portland, OR, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543391		19960806
APPLICATION INFO.:	US 1995-441770		19950516 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-246941, filed on 19 May 1994 which is a continuation-in-part of Ser. No. US 1993-142771, filed on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1992-911209, filed on 9 Jul 1992, now patented, Pat. No. US 5256641, issued on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1990-607982, filed on 1 Nov 1990, now patented, Pat. No. US 5149794, issued on 22 Sep 1992		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		
LEGAL REPRESENTATIVE:	Banner & Allegretti, Ltd.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1532		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle

L24 ANSWER 33 OF 38 USPATFULL (Continued)
 targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combatting and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.

L24 ANSWER 33 OF 38 USPATFULL
 ACCESSION NUMBER: 96:70430 USPATFULL
 TITLE: Covalent microparticle-drug conjugates for biological targeting
 INVENTOR(S): Yatvin, Milton B., Portland, OR, United States
 Stowell, Michael H. B., Pasadena, CA, United States
 Gallicchio, Vincent S., Lexington, KY, United States
 Meredith, Michael J., Lake Oswego, OR, United States
 PATENT ASSIGNEE(S): State of Oregon, Acting by and Through the Oregon Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University, Portland, OR, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543390		19960806
APPLICATION INFO.:	US 1994-246941		19940519 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-142771, filed on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1992-911209, filed on 9 Jul 1992, now patented, Pat. No. US 5256641, issued on 26 Oct 1993 which is a continuation-in-part of Ser. No. US 1990-607982, filed on 1 Nov 1990, now patented, Pat. No. US 5149794, issued on 22 Sep 1992		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		
LEGAL REPRESENTATIVE:	Banner & Allegretti, Ltd.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1554		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular

L24 ANSWER 33 OF 38 USPATFULL (Continued)
 organelles within the cell. Also provided are porous microparticles impregnated with antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combatting and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.

L24 ANSWER 34 OF 38 USPATFULL
 ACCESSION NUMBER: 96:34018 USPATFULL
 TITLE: Method of screening a peptide library
 INVENTOR(S): Lam, Kit S., Tucson, AZ, United States
 Salmon, Sydney E., Tucson, AZ, United States
 PATENT ASSIGNEE(S): The Arizona Board of Regents, Tucson, AZ, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5510240		19960423
APPLICATION INFO.:	US 1993-14979		19930208 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-717454, filed on 19 Jun 1991 which is a continuation-in-part of Ser. No. US 1990-546845, filed on 2 Jul 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Parr, Margaret		
ASSISTANT EXAMINER:	Sisson, Bradley Lounsbury		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	3392		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The instant invention provides a library of bio-oligomers of defined size and known composition, in which the library contains all of the possible sequences of the bio-oligomers, and a method of synthesis thereof. The bio-oligomers of the library may be peptides, nucleic acids, or a combination of the foregoing. The instant invention also provides methods to identify bio-oligomers from a library that demonstrate desired characteristics such as binding, bioactivity and catalytic activity. Thus the instant invention provides a unique and powerful method to identify a useful bio-oligomer sequences from a library more quickly than current state-of-the-art technology allows. Effector molecules for use in treatment or diagnosis of disease are also provided.

L24 ANSWER 35 OF 38 USPATFULL
 ACCESSION NUMBER: 95:5855 USPATFULL
 TITLE: Method of screening a peptide library
 INVENTOR(S): Lam, Kit S., Tucson, AZ, United States
 Salmon, Sydney E., Tucson, AZ, United States
 PATENT ASSIGNEE(S): Biologand Inc., Tucson, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5382513		19950117
APPLICATION INFO.:	US 1993-14979		19930208 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-717454, filed on 19 Jun 1991 which is a continuation-in-part of Ser. No. US 1990-546845, filed on 2 Jul 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Parr, Margaret		
ASSISTANT EXAMINER:	Sisson, Bradley Lounsbury		
LEGAL REPRESENTATIVE:	Pennie and Edmonds		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	3386		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The instant invention provides a library of bio-oligomers of defined size and known composition, in which the library contains all of the possible sequences of the bio-oligomers, and a method of synthesis thereof. The bio-oligomers of the library may be peptides, nucleic acids, or a combination of the foregoing. The instant invention also provides methods to identify bio-oligomers from a library that demonstrate desired characteristics such as binding, bioactivity and catalytic activity. Thus the instant invention provides a unique and powerful method to identify a useful bio-oligomer sequences from a library more quickly than current state-of-the-art technology allows. Effector molecules for use in treatment or diagnosis of disease are also provided.

L24 ANSWER 36 OF 38 USPATFULL
 ACCESSION NUMBER: 93:20521 USPATFULL
 TITLE: MHC-mediated toxic conjugates useful in ameliorating autoimmunity
 INVENTOR(S): Sharma, Somesh D., Los Altos, CA, United States
 Lerch, L. Bernard, Menlo Park, CA, United States
 Clark, Brian R., Redwood City, CA, United States
 PATENT ASSIGNEE(S): Amgen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5194425		19930316
APPLICATION INFO.:	US 1989-367751		19890621 (7)
DISCLAIMER DATE:	20090714		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-210594, filed on 23 Jun 1988		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine		
ASSISTANT EXAMINER:	Cunningham, T.		
LEGAL REPRESENTATIVE:	Townsend and Townsend		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	1401		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X_{sup.1} MHC_{sup.2} peptide or MHC_{sup.2} peptide_{sup.1} X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen; _{sup.1} represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and _{sup.2} represents a covalent bond, a noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.

L24 ANSWER 37 OF 38 USPATFULL
 ACCESSION NUMBER: 92:57662 USPATFULL
 TITLE: Conjugates useful in ameliorating
 autoimmunity MHC-II-peptide
 INVENTOR(S): Sharma, Suresh D., Los Altos, CA, United States
 Lerch, L. Bernard, Menlo Park, CA, United States
 Clark, Brian R., Redwood City, CA, United States
 PATENT ASSIGNEE(S): Anergis, Inc., Redwood City, CA, United States (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5130297		19920714
APPLICATION INFO.:	US 1990-576084		19900830 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-210594, filed on 23 Jun 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nuckner, Christine		
ASSISTANT EXAMINER:	Cunningham, T.		
LEGAL REPRESENTATIVE:	Townsend and Townsend		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	922		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods and materials useful in treating
 autoimmune diseases. The therapeutic agents
 are of the formula X--MHC--peptide or MHC--peptide
 --X wherein X represents a functional moiety selected from a toxin and
 a labeling group; MHC is an effective portion of the MHC glycoprotein,
 said glycoprotein dissociated from the cell surface on which it
 normally resides; and "peptide" represents an antigenic peptide
 sequence associated with an autoantigen; -- represents a covalent bond
 or a linker bound to X and MHC or to X and peptide by covalent
 bonds; and -- represents a covalent bond, to noncovalent association,
 or a linker covalently bound to or associated with the MHC and
 peptide. These complexes can be used to target helper
 T-cells which are specifically immunoreactive with autoantigens.

L24 ANSWER 38 OF 38 USPATFULL
 ACCESSION NUMBER: 86:69724 USPATFULL
 TITLE: Vitro diagnostic methods using monoclonal
 antibodies against connective tissue proteins
 INVENTOR(S): Gay, Steffen, Birmingham, AL, United States
 PATENT ASSIGNEE(S): Molecular Engineering Associates, Ltd., Birmingham,
 AL, United States (U.S. corporation)
 The Board of Trustees of the University of Alabama,
 Birmingham, AL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4628027		19861209
APPLICATION INFO.:	US 1984-601438		19840418 (6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1982-379704, filed on 19 May 1982, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Warren, Charles F.		
ASSISTANT EXAMINER:	Moskowitz, M.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1824		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Collagen profiles of human body tissues and fluids, i.e., the types of
 distinct connective tissue proteins present, their distribution in
 human body tissues and fluids, and the concentration ratios among distinct
 types, are subject to change during certain pathological conditions and
 during therapeutic regimens for the treatment of such
 conditions. These changes in collagen profiles can be detected by
 immunohistological, immunocytological and immunoserological techniques.
 In vitro diagnostic methods employing monoclonal antibodies
 specific for connective tissue proteins are provided which can be used
 for monitoring the results of therapeutic measures taken
 against inflammatory diseases, fibrotic diseases and
 cancer and for detecting or following the pathogenesis of such
 diseases.